{"id":"quizartinib","rwe":[],"_fda":{"id":"f306ed98-2cbf-48c7-8b9d-b9dfc5eb91a6","set_id":"29cdbcfe-497d-4e78-bb7b-2d4acafe8e86","openfda":{"unii":["WK7Q6ZIZ10"],"route":["ORAL"],"rxcui":["2643054","2643060","2643062","2643064"],"spl_id":["f306ed98-2cbf-48c7-8b9d-b9dfc5eb91a6"],"brand_name":["VANFLYTA"],"spl_set_id":["29cdbcfe-497d-4e78-bb7b-2d4acafe8e86"],"package_ndc":["65597-504-04","65597-504-28","65597-511-04","65597-511-28"],"product_ndc":["65597-504","65597-511"],"generic_name":["QUIZARTINIB"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["QUIZARTINIB DIHYDROCHLORIDE"],"manufacturer_name":["Daiichi Sankyo Inc."],"application_number":["NDA216993"],"is_original_packager":[true]},"version":"10","pregnancy":["8.1 Pregnancy Risk Summary Based on findings from animal studies and its mechanism of action, VANFLYTA can cause embryo-fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1) ] . There are no available data on VANFLYTA use in pregnant women to evaluate for a drug-associated risk. In animal reproduction studies, oral administration of quizartinib to pregnant rats during organogenesis resulted in adverse developmental outcomes including structural abnormalities and alterations to growth at maternal exposures approximately 3 times those in patients at the maximum recommended human dose (MRHD) of 53 mg/day ( see Data ). Advise pregnant women of the potential risk to a fetus. The background risk in the U.S. general population of major birth defects is 2-4%, and of miscarriage is 15-20% of clinically recognized pregnancies. Data Animal Data In an embryo-fetal development study in rats, pregnant animals received oral doses of quizartinib of 0, 0.6, 2, or 6 mg/kg/day during the period of organogenesis. Administration of quizartinib at the dose of 6 mg/kg/day was associated with adverse developmental outcomes including structural abnormalities (anasarca and edema) and alterations to growth (lower fetal weights and effects on skeletal ossification). At this dose, the maternal systemic exposures (AUC) were approximately 3 times the human exposure at the MRHD of 53 mg/day."],"description":["11 DESCRIPTION VANFLYTA (quizartinib) is a kinase inhibitor for oral use. The chemical name of quizartinib dihydrochloride is 1-(5- tert -butyl-1,2-oxazol-3-yl)-3-(4-{7-[2-(morpholin-4-yl)ethoxy]imidazo[2,1-b][1,3]benzothiazol-2-yl}phenyl)urea dihydrochloride. Quizartinib dihydrochloride is a white to off-white solid with a molecular formula of C 29 H 32 N 6 O 4 S∙2 HCl and a molecular weight of 633.6 for the salt and 560.7 for the free base. The aqueous solubility of quizartinib dihydrochloride (pKa 4.75 and 3.16) decreases with increasing pH. It is very slightly soluble in aqueous media at pH 1 and practically insoluble or insoluble at pH 2 and higher. Quizartinib dihydrochloride is very slightly soluble in ethanol. The chemical structure of quizartinib dihydrochloride is: VANFLYTA is supplied as film-coated tablets containing 17.7 mg or 26.5 mg of quizartinib, which are equivalent to 20 mg and 30 mg quizartinib dihydrochloride, respectively. The inactive ingredients in the tablet core are hydroxypropyl betadex, microcrystalline cellulose, and magnesium stearate. The tablet coating consists of hypromellose, talc, triacetin, and titanium dioxide. The 26.5 mg tablet coating also contains ferric oxide. Chemical Structure"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING VANFLYTA (quizartinib) is supplied as round, film-coated tablets, packaged in bottles with a child-resistant closure. Store at 20°C to 25°C (68°F to 77°F); excursions permitted from 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature]. Tablet Strength Tablet Description Package Configuration NDC 17.7 mg White, round, film-coated, debossed with \"DSC511\" , 28-count bottle 65597-504-28 14-count bottle 65597-504-04 26.5 mg Yellow, round, film-coated, debossed with \"DSC512\" 28-count bottle 65597-511-28 14-count bottle 65597-511-04"],"spl_medguide":["MEDICATION GUIDE VANFLYTA (van-FLITT-ah) (quizartinib) tablets This Medication Guide has been approved by the U.S. Food and Drug Administration. Issued: 7/2023 What is the most important information I should know about VANFLYTA? VANFLYTA may cause serious side effects, including: Changes in the electrical activity of your heart called QT prolongation, torsades de pointes, and your heart stopping (cardiac arrest). QT prolongation can cause irregular heartbeats that can be life-threatening or lead to death. Your healthcare provider will check the electrical activity of your heart with a test called an electrocardiogram (ECG) and will also do blood tests to check your potassium and magnesium levels before and during treatment with VANFLYTA. Tell your healthcare provider right away if you have an irregular heartbeat or feel dizzy, lightheaded, or faint, or have diarrhea or vomiting. VANFLYTA is available only through a restricted program called the VANFLYTA Risk Evaluation and Mitigation Strategy (REMS) due to the risk of QT prolongation, torsades de pointes, and cardiac arrest. You will receive a VANFLYTA Patient Wallet Card from your healthcare provider. Carry the VANFLYTA Patient Wallet Card with you at all times and show it to all of your healthcare providers. The VANFLYTA Patient Wallet Card lists signs and symptoms of QT prolongation and torsades de pointes. Get medical help right away if you develop any of the signs and symptoms listed on the VANFLYTA Patient Wallet Card. You may need to be treated in a hospital. See \" What are the possible side effects of VANFLYTA? \" for more information about side effects. What is VANFLYTA? VANFLYTA is a prescription medicine used in combination with certain chemotherapy medicines and alone as maintenance therapy to treat adults with newly diagnosed acute myeloid leukemia (AML) with a FLT3-ITD mutation. Your healthcare provider will perform a test to make sure that VANFLYTA is right for you. VANFLYTA is not for use alone as maintenance therapy after a hematopoietic stem cell transplant. It is not known if VANFLYTA is safe and effective in children. Do not take VANFLYTA if you have very low potassium, very low magnesium, long QT syndrome, or a history of ventricular arrhythmias or torsades de pointes. Before you take VANFLYTA, tell your healthcare provider about all of your medical conditions, including if you: have any heart problems. have low blood levels of potassium or magnesium. are pregnant or plan to become pregnant. VANFLYTA can harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with VANFLYTA. If you are able to become pregnant, your healthcare provider will perform a pregnancy test within 7 days before you start treatment with VANFLYTA. Females who are able to become pregnant should use effective birth control (contraception) during treatment with VANFLYTA and for 7 months after the last dose of VANFLYTA. Males who have female partners who are able to become pregnant should use effective birth control during treatment with VANFLYTA and for 4 months after the last dose of VANFLYTA. Talk to your healthcare provider about birth control methods you can use during this time. are breastfeeding or plan to breastfeed. It is not known if VANFLYTA passes into your breast milk. Do not breastfeed during treatment with VANFLYTA and for 1 month after the last dose of VANFLYTA. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. VANFLYTA and other medicines may affect each other causing side effects. Especially tell your healthcare provider if you take St. John's wort. You should not take St. John's wort during treatment with VANFLYTA. How should I take VANFLYTA? Take VANFLYTA exactly as your healthcare provider tells you to. Do not change your dose or stop taking VANFLYTA unless your healthcare provider tells you to. Take VANFLYTA by mouth 1 time a day at about the same time each day. Take VANFLYTA with or without food. Swallow VANFLYTA tablets whole. Do not cut, crush, or chew the tablets. If you miss a dose of VANFLYTA or did not take it at your usual time, take your dose as soon as possible on the same day. Take your next dose at your usual time on the next day. Do not take 2 doses on the same day to make up for a missed dose. If you vomit after taking a dose of VANFLYTA, do not take another dose. Take your next dose at your usual time the next day. What are the possible side effects of VANFLYTA? VANFLYTA may cause serious side effects, including: See \" What is the most important information I should know about VANFLYTA? \" The most common side effects of VANFLYTA include: low white blood cell counts changes in levels of electrolytes in the blood changes in liver function tests low white blood cell counts with fever diarrhea mouth sores nausea stomach (abdominal) pain serious infection throughout the body and organs (sepsis) headache vomiting upper respiratory tract infections low platelet counts decreased appetite fungal infections nosebleed herpesvirus infections trouble sleeping abnormal electrocardiogram (QT prolongation) upset stomach low red blood cell counts (anemia) eye irritation Your healthcare provider will do blood tests and ECGs before you start and during treatment with VANFLYTA. Your healthcare provider may tell you to decrease your dose, temporarily stop, or permanently stop taking VANFLYTA if you develop certain side effects during treatment with VANFLYTA. VANFLYTA may cause fertility problems in females and males, which may affect your ability to have children. Talk to your healthcare provider if you have concerns about fertility. These are not all the possible side effects of VANFLYTA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store VANFLYTA? Store VANFLYTA at room temperature between 68°F and 77°F (20°C and 25°C). Keep VANFLYTA and all medicines out of the reach of children. General information about the safe and effective use of VANFLYTA. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use VANFLYTA for a condition for which it is not prescribed. Do not give VANFLYTA to other people even if they have the same symptoms you have. It may harm them. You can ask your healthcare provider or pharmacist for information about VANFLYTA that is written for health professionals. What are the ingredients in VANFLYTA? Active ingredient: quizartinib Inactive ingredients: Tablet core: hydroxypropyl betadex, microcrystalline cellulose, and magnesium stearate. Tablet coating: hypromellose, talc, triacetin, and titanium dioxide. The 26.5 mg tablet coating also contains ferric oxide. Manufactured for: Daiichi Sankyo, Inc., Basking Ridge, NJ 07920 VANFLYTA ® is a registered trademark of Daiichi Sankyo Company, Ltd. Copyright © 2023, Daiichi Sankyo, Inc. USMG-VAN-C1-0723-r001 For more information about VANFLYTA, ask your healthcare provider or pharmacist, visit http://www.vanflyta.com, or call 1-877-437-7763."],"boxed_warning":["WARNING: QT PROLONGATION, TORSADES DE POINTES, and CARDIAC ARREST VANFLYTA prolongs the QT interval in a dose- and concentration-related manner [see Clinical Pharmacology (12.2) ] . Prior to VANFLYTA administration and periodically, monitor for hypokalemia or hypomagnesemia, and correct deficiencies. Perform ECGs to monitor the QTc at baseline, weekly during induction and consolidation therapy, weekly for at least the first month of maintenance, and periodically thereafter [see Dosage and Administration (2.3) and Warnings and Precautions (5.1) ]. Torsades de pointes and cardiac arrest have occurred in patients receiving VANFLYTA. Do not administer VANFLYTA to patients with severe hypokalemia, severe hypomagnesemia, or long QT syndrome [see Contraindications (4) and Warnings and Precautions (5.1) ] . Do not initiate treatment with VANFLYTA or escalate the VANFLYTA dose if the QT interval corrected by Fridericia's formula (QTcF) is greater than 450 ms [see Dosage and Administration (2.3) and Warnings and Precautions (5.1) ] . Monitor ECGs more frequently if concomitant use of drugs known to prolong the QT interval is required [see Dosage and Administration (2.3) and Warnings and Precautions (5.1) ] . Reduce the VANFLYTA dose when used concomitantly with strong CYP3A inhibitors, as they may increase quizartinib exposure [see Dosage and Administration (2.4) and Warnings and Precautions (5.1) ] . Because of the risk of QT prolongation, VANFLYTA is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the VANFLYTA REMS [see Warnings and Precautions (5.2) ] . WARNING: QT PROLONGATION, TORSADES DE POINTES, and CARDIAC ARREST See full prescribing information for complete boxed warning. VANFLYTA prolongs the QT interval. ( 12.2 ) Prior to VANFLYTA administration and periodically, perform electrocardiograms (ECGs), monitor for hypokalemia or hypomagnesemia, and correct deficiencies. ( 2.3 , 5.1 ) Torsades de pointes and cardiac arrest have occurred in patients receiving VANFLYTA. Do not administer VANFLYTA to patients with severe hypokalemia, severe hypomagnesemia, or long QT syndrome. ( 4 , 5.1 ) Do not initiate treatment with VANFLYTA or escalate the VANFLYTA dose if the QT interval corrected by Fridericia's formula (QTcF) is greater than 450 ms. ( 2.3 , 5.1 ) Monitor ECGs more frequently if concomitant use of drugs known to prolong the QT interval is required. ( 2.3 , 5.1 ) Reduce the VANFLYTA dose when used concomitantly with strong CYP3A inhibitors, as they may increase quizartinib exposure. ( 2.4 , 5.1 ) VANFLYTA is available only through a restricted program called the VANFLYTA Risk Evaluation and Mitigation Strategy (REMS). ( 5.2 )"],"geriatric_use":["8.5 Geriatric Use There were 533 patients with newly diagnosed AML in the clinical study; of the total number of VANFLYTA-treated patients, 69 (26%) were 65 years of age and older, while 1 (0.4%) was 75 years of age [see Clinical Studies (14) ] . No overall differences in safety or efficacy were observed between patients 65 years of age and older and younger adult patients."],"pediatric_use":["8.4 Pediatric Use Safety and effectiveness of VANFLYTA have not been established in pediatric patients."],"effective_time":"20251112","clinical_studies":["14 CLINICAL STUDIES The efficacy of VANFLYTA in combination with chemotherapy was evaluated in QuANTUM-First (NCT02668653), a randomized, double-blind, placebo-controlled study of 539 patients with newly diagnosed FLT3-ITD positive AML. FLT3-ITD status was determined prospectively with a clinical trial assay and verified retrospectively using the companion diagnostic LeukoStrat ® CDx FLT3 Mutation Assay, which is an FDA-approved test for selection of patients with AML for VANFLYTA treatment. Patients were stratified by age (<60 versus ≥60 years), white blood cell count at diagnosis (<40×10 9 /L versus ≥40×10 9 /L), and region (North America, Europe versus Asia, other regions). Patients were randomized (1:1) to receive VANFLYTA (n=268) or placebo (n=271) in combination with induction and consolidation therapy and as maintenance monotherapy according to the initial assignment, as follows: a) Induction : 35.4 mg orally once daily on Days 8-21 of 7 + 3 (cytarabine [100 or 200 mg/m 2 /day] on Days 1 to 7 plus daunorubicin [60 mg/m 2 /day] or idarubicin [12 mg/m 2 /day] on Days 1 to 3) and on Days 8-21 or 6-19 of an optional second induction (7 + 3 or 5 + 2 [5 days cytarabine plus 2 days daunorubicin or idarubicin], respectively), b) Consolidation : 35.4 mg orally once daily on Days 6-19 of high-dose cytarabine (1.5 to 3 g/m 2 every 12 hours on Days 1, 3 and 5) for up to 4 cycles, and c) Maintenance : 26.5 mg orally once daily on Days 1 to 14 and 53 mg once daily thereafter for up to thirty-six 28-day cycles. There was no re-randomization at the start of post consolidation therapy. Patients who proceeded to hematopoietic stem cell transplantation (HSCT) initiated maintenance therapy after recovery from the HSCT. The two treatment groups were generally balanced with respect to baseline demographics and disease characteristics. Of the 539 randomized patients, the median age was 56 years (range 20-75 years); 46% were male; 60% were White, 29% were Asian, 1% were Black, and 10% were other races. Eighty-four percent had an Eastern Cooperative Oncology Group (ECOG) baseline performance status of 0 or 1. The majority of the patients (72%) had intermediate risk cytogenetics at baseline. FLT3-ITD variant allelic frequency (VAF) was 3-25% in 36% of patients, >25-50% in 52% of patients, and >50% in 12% of patients. NPM1 mutations were identified in 52% of patients. A second course of induction was administered to 20% of the patients, 65% initiated at least one cycle of consolidation, and 39% initiated maintenance. Among the patients who entered maintenance, 64% completed at least 12 cycles, 36% completed at least 24 cycles, and 16% completed all 36 planned cycles of maintenance. Twenty-nine percent (157/539) of the patients underwent HSCT in first complete remission (CR). The overall rate of HSCT (including the following settings: first CR, induction failure, or salvage after relapse) was 54% (144/268) in the VANFLYTA plus standard chemotherapy arm versus 47% (128/271) in the placebo plus standard chemotherapy arm. All patients were followed for survival. Efficacy was established on the basis of overall survival (OS), measured from the date of randomization until death by any cause. The primary analysis was conducted after a minimum follow-up of 24 months after the randomization of the last patient. The study demonstrated a statistically significant improvement in OS for the VANFLYTA arm [hazard ratio (HR) 0.78; 95% CI: 0.62, 0.98; 2-sided p=0.0324] (see Figure 1 ). Figure 1: Kaplan-Meier Curve for Overall Survival in QuANTUM-First In an exploratory subgroup analysis of the 89/208 (43%) of patients who received maintenance therapy with VANFLYTA or placebo following consolidation chemotherapy, the OS HR was 0.40 (95% CI: 0.19, 0.84). Of 119/208 (57%) of patients who received maintenance therapy with VANFLYTA or placebo following HSCT, the OS HR was 1.62 (95% CI: 0.62, 4.22). The CR rate in the VANFLYTA arm was 55% (95% CI: 48.7, 60.9) with a median duration of CR of 38.6 months (95% CI: 21.9, NE), and the CR rate in the placebo arm was 55% (95% CI: 49.2, 61.4) with a median duration of CR of 12.4 months (95% CI: 8.8, 22.7). Figure 1"],"pharmacodynamics":["12.2 Pharmacodynamics The exposure-response relationship and time course of pharmacodynamic response for the safety and effectiveness of quizartinib have not been fully characterized. Cardiac Electrophysiology In vitro studies have shown that quizartinib is a predominant inhibitor of the slow delayed rectifier potassium current, I Ks . The exposure-response analysis predicted a concentration-dependent QTcF interval median prolongation of 18 and 24 ms [upper bound of 2-sided 90% confidence interval (CI): 21 and 27 ms] at the median steady-state C max of quizartinib at the 26.5 mg and 53 mg dose level during maintenance therapy [see Warnings and Precautions (5.1) and Drug Interactions (7) ] ."],"pharmacokinetics":["12.3 Pharmacokinetics The pharmacokinetics of quizartinib and its major circulating active metabolite (AC886) were characterized in healthy subjects and in patients with cancer and are presented as geometric mean (percent coefficient of variation [%CV]) unless otherwise specified. Steady state quizartinib concentrations were achieved at Day 15 following once daily dosage in patients with AML. Quizartinib exposure (AUC and C max ) increased proportionally in the dose range of 26.5 mg (0.75 times the recommended 35.4 mg induction dose) to 79.5 mg (2.25 times the recommended 35.4 mg induction dose) in healthy subjects and 17.7 mg (0.5 times the recommended 35.4 mg induction dose) to 53 mg (1.5 times the recommended 35.4 mg induction dose) in patients with AML. Table 8: Pharmacokinetic Properties of Quizartinib and AC886 Quizartinib AC886 General Information Steady state exposure following 35.4 mg VANFLYTA once daily during induction therapy in patients with newly diagnosed AML C max 140 ng/mL (71%) 163 ng/mL (52%) AUC 0-24h 2,680 ng∙h/mL (85%) 3,590 ng∙h/mL (51%) Steady state exposure following 35.4 mg VANFLYTA once daily during consolidation therapy in patients with newly diagnosed AML C max 204 ng/mL (64%) 172 ng/mL (47%) AUC 0-24h 3,930 ng∙h/mL (78%) 3,800 ng∙h/mL (46%) Steady state exposure following 53 mg VANFLYTA once daily during maintenance therapy in patients with newly diagnosed AML C max 529 ng/mL (60%) 262 ng/mL (48%) AUC 0-24h 10,200 ng∙h/mL (75%) 5,790 ng∙h/mL (46%) Accumulation ratio Mean (±SD) (AUC 0-24h ) 5.4 (4.4) 8.7 (6.8) Absorption The mean (SD) absolute bioavailability of quizartinib from the tablet formulation was 71% (±7%) in healthy subjects. After oral administration under fasted conditions, time to peak concentration (median T max ) of quizartinib and AC886 measured post dose was approximately 4 hours (range 2 to 8 hours) and 5 to 6 hours (range 4 to 120 hours), respectively, in healthy subjects. No clinically significant differences in the pharmacokinetics of quizartinib were observed when administered with a high-fat, high-calorie meal. Distribution Volume of distribution at steady state in healthy subjects was estimated to be 275 L (17%). In vitro plasma protein binding of quizartinib and AC886 is 99% or greater. In vitro blood-to-plasma ratio for quizartinib and AC886 ranges from 0.79-1.30 and 1.36-3.19, respectively. Elimination Total body clearance of quizartinib in healthy subjects was estimated to be 2.23 L/hour (29%). The mean (SD) effective half-lives (t 1/2 ) in patients with newly diagnosed AML for quizartinib and AC886 during maintenance therapy are 81 hours (±73) and 136 hours (±113), respectively. Metabolism In vitro quizartinib is primarily metabolized via oxidation by CYP3A4/5 and AC886 is formed and metabolized by CYP3A4/5. Excretion Following a single radiolabeled dose of quizartinib 53 mg to healthy subjects, 76.3% of the total radioactivity was recovered in feces (4% unchanged) and 1.64% in urine. Specific Populations There were no clinically significant differences in the exposure of quizartinib and AC886 based on age (range 18 to 91 years), sex, race (White 65%, Asian 18%, Black 9%), or body weight (range 37 to 153 kg). Patients with Renal Impairment Mild or moderate renal impairment (i.e., estimated creatinine clearance [CLcr] by Cockcroft-Gault equation: 30 to 89 mL/min) were not associated with clinically significant differences in the exposure of quizartinib and AC886. The impact of severe renal impairment (CLcr <30 mL/min) on the pharmacokinetics of quizartinib and AC886 is unknown [see Use in Specific Populations (8.6) ] . Patients with Hepatic Impairment Mild (total bilirubin ≤ upper limit of normal [ULN] and aspartate aminotransferase [AST] >ULN or total bilirubin >1 to 1.5 times ULN and any value for AST) or moderate (total bilirubin >1.5 to 3 times ULN and any value for AST) hepatic impairment were not associated with clinically significant differences in the exposure of quizartinib and AC886. The impact of severe hepatic impairment (Child-Pugh Class C or total bilirubin >3 times ULN and any value for AST) on the pharmacokinetics of quizartinib and AC886 is unknown [see Use in Specific Populations (8.7) ] . Drug Interaction Studies and Model-Informed Approaches Clinical Studies Strong CYP3A Inhibitors The AUC of quizartinib increased by 94% and the C max by 17% following coadministration of a single 53 mg quizartinib dose with ketoconazole (a strong CYP3A inhibitor). The AUCinf of AC886 decreased by 94% and C max by 60%. Moderate CYP3A Inhibitors A clinically significant change in quizartinib and AC886 exposure (C max and AUC inf ) was not observed following coadministration of a single quizartinib dose with fluconazole (a moderate CYP3A inhibitor). Strong or Moderate CYP3A Inducers The AUC inf of quizartinib decreased by 90% and C max by 45% following concomitant use of a single 53 mg dose of quizartinib with efavirenz (a moderate CYP3A inducer). The AUC of AC886 decreased by 96% and the C max by 68%. The effect of concomitant use with a strong CYP3A inducer may result in even greater effect on quizartinib pharmacokinetics based on mechanistic understanding of the drugs involved. Gastric Acid Reducing Agents No clinically significant differences in quizartinib pharmacokinetics were observed when used concomitantly with lansoprazole (a proton pump inhibitor that reduces gastric acid). Other Drugs There were no clinically significant differences in the pharmacokinetics of P-gp substrates (dabigatran etexilate) or UGT1A1 substrates (raltegravir) when used concomitantly with quizartinib. In Vitro Studies Cytochrome P450 (CYP) Enzymes Quizartinib does not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4. Quizartinib does not induce CYP3A4, CYP1A2, or CYP2B6. AC886 does not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2D6, CYP2C19, or CYP3A4. AC886 does not induce CYP3A4, CYP1A2, or CYP2B6. Other Metabolic Pathways Quizartinib inhibits UGT1A1. Transporters Quizartinib is a substrate for P-gp but not for BCRP, OATP1B1, OATP1B3, OCT1, OAT2, MATE1, or MRP2. AC886 is a substrate for BCRP but not for OATP1B1, OATP1B3, MATE1, or MRP2. Quizartinib inhibits BCRP and inhibition of this transporter at the recommended dosage cannot be excluded."],"adverse_reactions":["6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: QT Prolongation, Torsades de Pointes, and Cardiac Arrest [see Warnings and Precautions (5.1) ] The most common (>20%) adverse reactions, including laboratory abnormalities, are lymphocytes decreased, potassium decreased, albumin decreased, phosphorus decreased, alkaline phosphatase increased, magnesium decreased, febrile neutropenia, diarrhea, mucositis, nausea, calcium decreased, abdominal pain, sepsis, neutropenia, headache, creatine phosphokinase increased, vomiting, and upper respiratory tract infection. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Daiichi Sankyo, Inc. at 1-877-437-7763 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Newly Diagnosed FLT3-ITD positive AML The safety of VANFLYTA (35.4 mg orally once daily with chemotherapy, 26.5 mg to 53 mg orally once daily as maintenance) in adult patients with newly diagnosed FLT3-ITD positive AML is based on QuANTUM-First, a randomized, double-blind clinical trial of VANFLYTA (n=265) or placebo (n=268) with chemotherapy [see Clinical Studies (14) ] . Among patients who received VANFLYTA, 38% were exposed for 6 months or longer and 30% were exposed for greater than one year. On the VANFLYTA plus chemotherapy arm, 65% and 44% of patients completed induction and consolidation therapy, respectively, compared to 65% and 34% of patients in the placebo plus chemotherapy arm. Serious adverse reactions in ≥5% of patients who received VANFLYTA plus chemotherapy were: febrile neutropenia (11%). Fatal adverse reactions occurred in 10% of patients who received VANFLYTA plus chemotherapy, including sepsis (5%), fungal infections (0.8%), brain edema (0.8%), and one case each of febrile neutropenia, pneumonia, cerebral infarction, acute respiratory distress syndrome, pulmonary embolism, ventricular dysfunction, and cardiac arrest. Permanent discontinuation due to an adverse reaction in patients in the VANFLYTA plus chemotherapy arm occurred in 20% of patients. The most frequent (≥2%) adverse reaction which resulted in permanent discontinuation in the VANFLYTA arm was sepsis (5%). Dosage interruptions of VANFLYTA due to an adverse reaction occurred in 34% of patients. Adverse reactions which required dosage interruption in ≥2% of patients in the VANFLYTA arm included neutropenia (11%), thrombocytopenia (5%), and myelosuppression (3%). Dose reductions of VANFLYTA due to an adverse reaction occurred in 19% of patients. Adverse reactions which required dosage reductions in ≥2% of patients in the VANFLYTA arm were neutropenia (9%), thrombocytopenia (5%), and electrocardiogram QT prolonged (4%). The most common adverse reactions (≥10% with a difference between arms of ≥2% compared to placebo), including laboratory abnormalities, were lymphocytes decreased, potassium decreased, albumin decreased, phosphorus decreased, alkaline phosphatase increased, magnesium decreased, febrile neutropenia, diarrhea, mucositis, nausea, calcium decreased, abdominal pain, sepsis, neutropenia, headache, creatine phosphokinase increased, vomiting, upper respiratory tract infections, hypertransaminasemia, thrombocytopenia, decreased appetite, fungal infections, epistaxis, potassium increased, herpesvirus infections, insomnia, electrocardiogram QT prolonged, magnesium increased, sodium increased, dyspepsia, anemia, and eye irritation. Tables 5 and 6 summarize adverse reactions and laboratory abnormalities observed in patients receiving VANFLYTA in the clinical trial. Table 5: Adverse Reactions (≥10%) in Patients with Newly Diagnosed FLT3-ITD positive AML Who Received VANFLYTA (with a Difference Between Arms of ≥2% Compared to Placebo) in the Clinical Trial Body System Adverse Reaction VANFLYTA + Chemotherapy (N=265) PLACEBO + Chemotherapy (N=268) All Grades % Grade 3 or 4 % All Grades % Grade 3 or 4 % Blood and Lymphatic System Disorders Febrile neutropenia Including fatalities. 44 43 42 41 Neutropenia Includes other related terms. 29 26 14 12 Thrombocytopenia 18 13 13 12 Anemia 11 6 7 5 Gastrointestinal Disorders Diarrhea Diarrhea includes colitis, diarrhea, enteritis, enterocolitis, gastroenteritis, and neutropenic colitis. 42 8 39 8 Mucositis Mucositis includes anal inflammation, anal ulcer, anorectal discomfort, aphthous ulcer, laryngeal inflammation, laryngeal pain, mucosal inflammation, edema mucosal, esophageal pain, esophageal ulcer, esophagitis, oral blood blister, oral disorder, oral mucosa erosion, oral mucosal blistering, oral mucosal erythema, oral pain, oropharyngeal pain, pharyngeal inflammation, proctalgia, proctitis, stomatitis, tongue ulceration, and vaginal ulceration. 38 5 33 4.1 Nausea 34 1.5 31 1.9 Abdominal pain 30 2.3 22 1.1 Vomiting 25 0 20 1.5 Dyspepsia 11 0.4 9 0.7 Infections and Infestations Sepsis Sepsis includes acinetobacter infection, bacteremia, bacterial sepsis, corynebacterium bacteremia, device related bacteremia, device related sepsis, enterobacter sepsis, enterococcal bacteremia, enterococcal sepsis, escherichia bacteremia, escherichia sepsis, klebsiella bacteremia, klebsiella sepsis, neutropenic sepsis, pseudomonal bacteremia, pulmonary sepsis, sepsis, septic shock, staphylococcal bacteremia, staphylococcal infection, staphylococcal sepsis, stenotrophomonas sepsis, streptococcal sepsis, and streptococcal bacteremia. , 30 19 26 20 Upper respiratory tract infection 21 2.6 12 3 Fungal infection Fungal infection includes aspergillosis oral, aspergillus infection, bronchopulmonary aspergillosis, candida infection, candida sepsis, fungal infection, fungal sepsis, fungal skin infection, fusarium infection, gastrointestinal candidiasis, hepatic infection fungal, hepatosplenic candidiasis, lower respiratory tract infection fungal, mucormycosis, oral candidiasis, oral fungal infection, oropharyngeal candidiasis, systemic candida, systemic mycosis, tinea cruris, and vulvovaginal candidiasis. , 16 6 10 3 Herpesvirus infection Herpesvirus infection includes disseminated varicella zoster virus infection, genital herpes, herpes simplex, herpesvirus infection, herpes zoster, oral herpes, and varicella zoster virus infection. 14 2.6 8 1.9 Nervous System Disorders Headache 28 0 20 0.7 Hepatobiliary disorders Hypertransaminasemia Hypertransaminasemia includes alanine aminotransferase increased, aspartate aminotransferase increased, transaminases increased, hepatic enzymes increased, and hypertransaminasemia. 19 7 14 6 Metabolism and Nutrition Disorders Decreased appetite 17 4.9 13 1.9 Respiratory, Thoracic and Mediastinal Disorders Epistaxis 15 1.1 11 0.4 Psychiatric Disorders Insomnia 14 0 11 0 Investigations Electrocardiogram QT prolonged 14 3 4.1 1.1 Eye Disorders Eye irritation Eye irritation includes dry eye, eye inflammation, eye irritation, eye pain, eye pruritus, foreign body sensation in eyes, keratitis, and ulcerative keratitis. 11 0 7 0 Laboratory Abnormalities Prolonged thrombocytopenia or neutropenia in the absence of active leukemia lasting past cycle day 42 of induction cycle 1 were noted in 8% of patients on the VANFLYTA plus chemotherapy arm and 4% of patients in the placebo plus chemotherapy arm. Table 6: Select Laboratory Abnormalities (≥10%) That Worsened from Baseline in Patients with Newly Diagnosed FLT3-ITD positive AML (with a Difference Between Arms of ≥2% Compared to Placebo) in the Clinical Trial Laboratory Abnormality VANFLYTA + Chemotherapy The denominator used to calculate the rate varied from 199 to 260 in VANFLYTA + Chemotherapy and from 187 to 267 in PLACEBO + Chemotherapy based on the number of patients with a baseline value and at least one post-treatment value. PLACEBO + Chemotherapy All Grades% Grades 3 or 4% All Grades% Grades 3 or 4% Lymphocytes decreased 60 57 55 51 Potassium decreased 59 22 56 18 Albumin decreased 53 1.6 45 4.3 Phosphorus decreased 52 22 48 19 Alkaline phosphatase increased 51 1.6 47 1.9 Magnesium decreased 44 2 42 1.1 Calcium decreased 33 2.4 27 1.6 Creatine phosphokinase increased 26 2.5 7 0.5 Potassium increased 15 1.2 11 0.8 Magnesium increased 14 2.8 9 1.2 Sodium increased 13 0 10 0.4 Other Clinical Trials Clinically relevant adverse reactions in <10% of patients who received quizartinib for relapsed or refractory FLT3-ITD positive AML, an indication for which VANFLYTA is not approved, included differentiation syndrome (5%) and acute febrile neutrophilic dermatosis (3%)."],"contraindications":["4 CONTRAINDICATIONS VANFLYTA is contraindicated in patients with severe hypokalemia, severe hypomagnesemia, long QT syndrome, or in patients with a history of ventricular arrhythmias or torsades de pointes [see Warnings and Precautions (5.1) ]. Contraindicated in patients with severe hypokalemia, severe hypomagnesemia, long QT syndrome, or in patients with a history of ventricular arrhythmias or torsades de pointes. ( 4 , 5.1 )"],"drug_interactions":["7 DRUG INTERACTIONS Table 7: Effect of Other Drugs on VANFLYTA Strong CYP3A Inhibitors Clinical Impact VANFLYTA is a CYP3A substrate. Concomitant use of VANFLYTA with a strong CYP3A inhibitor increases quizartinib systemic exposure [see Clinical Pharmacology (12.3) ] , which may increase the risk of VANFLYTA adverse reactions. Prevention or Management Reduce the dosage of VANFLYTA [see Dosage and Administration (2.4) ]. Strong or Moderate CYP3A Inducers Clinical Impact Concomitant use of VANFLYTA with strong or moderate CYP3A inducers decreases quizartinib systemic exposure [see Clinical Pharmacology (12.3) ] , which may reduce VANFLYTA efficacy. Prevention or Management Avoid concomitant use of VANFLYTA with strong or moderate CYP3A inducers [see Clinical Pharmacology (12.3) ] . QT Interval Prolonging Drugs Clinical Impact VANFLYTA prolongs the QT/QTc interval. Coadministration of VANFLYTA with other drugs that prolong the QT interval may further increase the incidence of QT prolongation [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.2) ] . Prevention or Management Monitor patients more frequently with ECG if coadministration of VANFLYTA with drugs known to prolong the QT interval is required. Examples of QT prolonging drugs include but are not limited to antifungal azoles, ondansetron, granisetron, azithromycin, pentamidine, doxycycline, moxifloxacin, atovaquone, prochlorperazine, and tacrolimus. Strong CYP3A Inhibitors: Reduce the VANFLYTA dose. ( 2.4 , 7 ) Strong or Moderate CYP3A Inducers: Avoid concomitant use. ( 7 , 12.3 )"],"how_supplied_table":["
Tablet StrengthTablet DescriptionPackage ConfigurationNDC
17.7 mgWhite, round, film-coated, debossed with "DSC511",28-count bottle65597-504-28
14-count bottle65597-504-04
26.5 mgYellow, round, film-coated, debossed with "DSC512"28-count bottle65597-511-28
14-count bottle65597-511-04
"],"spl_medguide_table":["
MEDICATION GUIDE VANFLYTA (van-FLITT-ah) (quizartinib) tablets
This Medication Guide has been approved by the U.S. Food and Drug Administration.Issued: 7/2023
What is the most important information I should know about VANFLYTA? VANFLYTA may cause serious side effects, including:Changes in the electrical activity of your heart called QT prolongation, torsades de pointes, and your heart stopping (cardiac arrest). QT prolongation can cause irregular heartbeats that can be life-threatening or lead to death. Your healthcare provider will check the electrical activity of your heart with a test called an electrocardiogram (ECG) and will also do blood tests to check your potassium and magnesium levels before and during treatment with VANFLYTA. Tell your healthcare provider right away if you have an irregular heartbeat or feel dizzy, lightheaded, or faint, or have diarrhea or vomiting.VANFLYTA is available only through a restricted program called the VANFLYTA Risk Evaluation and Mitigation Strategy (REMS) due to the risk of QT prolongation, torsades de pointes, and cardiac arrest. You will receive a VANFLYTA Patient Wallet Card from your healthcare provider. Carry the VANFLYTA Patient Wallet Card with you at all times and show it to all of your healthcare providers. The VANFLYTA Patient Wallet Card lists signs and symptoms of QT prolongation and torsades de pointes. Get medical help right away if you develop any of the signs and symptoms listed on the VANFLYTA Patient Wallet Card. You may need to be treated in a hospital. See "What are the possible side effects of VANFLYTA?" for more information about side effects.
What is VANFLYTA? VANFLYTA is a prescription medicine used in combination with certain chemotherapy medicines and alone as maintenance therapy to treat adults with newly diagnosed acute myeloid leukemia (AML) with a FLT3-ITD mutation. Your healthcare provider will perform a test to make sure that VANFLYTA is right for you. VANFLYTA is not for use alone as maintenance therapy after a hematopoietic stem cell transplant. It is not known if VANFLYTA is safe and effective in children.
Do not take VANFLYTA if you have very low potassium, very low magnesium, long QT syndrome, or a history of ventricular arrhythmias or torsades de pointes.
Before you take VANFLYTA, tell your healthcare provider about all of your medical conditions, including if you:have any heart problems.have low blood levels of potassium or magnesium.are pregnant or plan to become pregnant. VANFLYTA can harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with VANFLYTA. If you are able to become pregnant, your healthcare provider will perform a pregnancy test within 7 days before you start treatment with VANFLYTA.Females who are able to become pregnant should use effective birth control (contraception) during treatment with VANFLYTA and for 7 months after the last dose of VANFLYTA.Males who have female partners who are able to become pregnant should use effective birth control during treatment with VANFLYTA and for 4 months after the last dose of VANFLYTA.Talk to your healthcare provider about birth control methods you can use during this time.are breastfeeding or plan to breastfeed. It is not known if VANFLYTA passes into your breast milk. Do not breastfeed during treatment with VANFLYTA and for 1 month after the last dose of VANFLYTA.Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. VANFLYTA and other medicines may affect each other causing side effects. Especially tell your healthcare provider if you take St. John's wort. You should not take St. John's wort during treatment with VANFLYTA.
How should I take VANFLYTA?Take VANFLYTA exactly as your healthcare provider tells you to. Do not change your dose or stop taking VANFLYTA unless your healthcare provider tells you to.Take VANFLYTA by mouth 1 time a day at about the same time each day.Take VANFLYTA with or without food.Swallow VANFLYTA tablets whole. Do not cut, crush, or chew the tablets.If you miss a dose of VANFLYTA or did not take it at your usual time, take your dose as soon as possible on the same day. Take your next dose at your usual time on the next day. Do not take 2 doses on the same day to make up for a missed dose.If you vomit after taking a dose of VANFLYTA, do not take another dose. Take your next dose at your usual time the next day.
What are the possible side effects of VANFLYTA? VANFLYTA may cause serious side effects, including:See "What is the most important information I should know about VANFLYTA?"The most common side effects of VANFLYTA include:
low white blood cell countschanges in levels of electrolytes in the bloodchanges in liver function testslow white blood cell counts with fever diarrheamouth soresnauseastomach (abdominal) painserious infection throughout the body and organs (sepsis)headachevomitingupper respiratory tract infectionslow platelet countsdecreased appetitefungal infectionsnosebleedherpesvirus infectionstrouble sleepingabnormal electrocardiogram (QT prolongation)upset stomachlow red blood cell counts (anemia)eye irritation
Your healthcare provider will do blood tests and ECGs before you start and during treatment with VANFLYTA. Your healthcare provider may tell you to decrease your dose, temporarily stop, or permanently stop taking VANFLYTA if you develop certain side effects during treatment with VANFLYTA. VANFLYTA may cause fertility problems in females and males, which may affect your ability to have children. Talk to your healthcare provider if you have concerns about fertility. These are not all the possible side effects of VANFLYTA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store VANFLYTA?Store VANFLYTA at room temperature between 68°F and 77°F (20°C and 25°C).Keep VANFLYTA and all medicines out of the reach of children.
General information about the safe and effective use of VANFLYTA. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use VANFLYTA for a condition for which it is not prescribed. Do not give VANFLYTA to other people even if they have the same symptoms you have. It may harm them. You can ask your healthcare provider or pharmacist for information about VANFLYTA that is written for health professionals.
What are the ingredients in VANFLYTA? Active ingredient: quizartinib Inactive ingredients:Tablet core: hydroxypropyl betadex, microcrystalline cellulose, and magnesium stearate.Tablet coating: hypromellose, talc, triacetin, and titanium dioxide. The 26.5 mg tablet coating also contains ferric oxide.Manufactured for: Daiichi Sankyo, Inc., Basking Ridge, NJ 07920 VANFLYTA® is a registered trademark of Daiichi Sankyo Company, Ltd. Copyright © 2023, Daiichi Sankyo, Inc. USMG-VAN-C1-0723-r001 For more information about VANFLYTA, ask your healthcare provider or pharmacist, visit http://www.vanflyta.com, or call 1-877-437-7763.
"],"mechanism_of_action":["12.1 Mechanism of Action Quizartinib is a small molecule inhibitor of the receptor tyrosine kinase FLT3. Quizartinib and its major active metabolite AC886 bind to the adenosine triphosphate (ATP) binding domain of FLT3 with comparable affinity, and both had 10-fold lower affinity towards FLT3-ITD mutation compared to FLT3 in a binding assay. Quizartinib and AC886 inhibited FLT3 kinase activity, preventing autophosphorylation of the receptor, thereby inhibiting downstream FLT3 receptor signaling and blocking FLT3-ITD-dependent cell proliferation. Quizartinib showed antitumor activity in a mouse model of FLT3-ITD-dependent leukemia."],"storage_and_handling":["Store at 20°C to 25°C (68°F to 77°F); excursions permitted from 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature]. Tablet Strength Tablet Description Package Configuration NDC 17.7 mg White, round, film-coated, debossed with \"DSC511\" , 28-count bottle 65597-504-28 14-count bottle 65597-504-04 26.5 mg Yellow, round, film-coated, debossed with \"DSC512\" 28-count bottle 65597-511-28 14-count bottle 65597-511-04"],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Quizartinib is a small molecule inhibitor of the receptor tyrosine kinase FLT3. Quizartinib and its major active metabolite AC886 bind to the adenosine triphosphate (ATP) binding domain of FLT3 with comparable affinity, and both had 10-fold lower affinity towards FLT3-ITD mutation compared to FLT3 in a binding assay. Quizartinib and AC886 inhibited FLT3 kinase activity, preventing autophosphorylation of the receptor, thereby inhibiting downstream FLT3 receptor signaling and blocking FLT3-ITD-dependent cell proliferation. Quizartinib showed antitumor activity in a mouse model of FLT3-ITD-dependent leukemia. 12.2 Pharmacodynamics The exposure-response relationship and time course of pharmacodynamic response for the safety and effectiveness of quizartinib have not been fully characterized. Cardiac Electrophysiology In vitro studies have shown that quizartinib is a predominant inhibitor of the slow delayed rectifier potassium current, I Ks . The exposure-response analysis predicted a concentration-dependent QTcF interval median prolongation of 18 and 24 ms [upper bound of 2-sided 90% confidence interval (CI): 21 and 27 ms] at the median steady-state C max of quizartinib at the 26.5 mg and 53 mg dose level during maintenance therapy [see Warnings and Precautions (5.1) and Drug Interactions (7) ] . 12.3 Pharmacokinetics The pharmacokinetics of quizartinib and its major circulating active metabolite (AC886) were characterized in healthy subjects and in patients with cancer and are presented as geometric mean (percent coefficient of variation [%CV]) unless otherwise specified. Steady state quizartinib concentrations were achieved at Day 15 following once daily dosage in patients with AML. Quizartinib exposure (AUC and C max ) increased proportionally in the dose range of 26.5 mg (0.75 times the recommended 35.4 mg induction dose) to 79.5 mg (2.25 times the recommended 35.4 mg induction dose) in healthy subjects and 17.7 mg (0.5 times the recommended 35.4 mg induction dose) to 53 mg (1.5 times the recommended 35.4 mg induction dose) in patients with AML. Table 8: Pharmacokinetic Properties of Quizartinib and AC886 Quizartinib AC886 General Information Steady state exposure following 35.4 mg VANFLYTA once daily during induction therapy in patients with newly diagnosed AML C max 140 ng/mL (71%) 163 ng/mL (52%) AUC 0-24h 2,680 ng∙h/mL (85%) 3,590 ng∙h/mL (51%) Steady state exposure following 35.4 mg VANFLYTA once daily during consolidation therapy in patients with newly diagnosed AML C max 204 ng/mL (64%) 172 ng/mL (47%) AUC 0-24h 3,930 ng∙h/mL (78%) 3,800 ng∙h/mL (46%) Steady state exposure following 53 mg VANFLYTA once daily during maintenance therapy in patients with newly diagnosed AML C max 529 ng/mL (60%) 262 ng/mL (48%) AUC 0-24h 10,200 ng∙h/mL (75%) 5,790 ng∙h/mL (46%) Accumulation ratio Mean (±SD) (AUC 0-24h ) 5.4 (4.4) 8.7 (6.8) Absorption The mean (SD) absolute bioavailability of quizartinib from the tablet formulation was 71% (±7%) in healthy subjects. After oral administration under fasted conditions, time to peak concentration (median T max ) of quizartinib and AC886 measured post dose was approximately 4 hours (range 2 to 8 hours) and 5 to 6 hours (range 4 to 120 hours), respectively, in healthy subjects. No clinically significant differences in the pharmacokinetics of quizartinib were observed when administered with a high-fat, high-calorie meal. Distribution Volume of distribution at steady state in healthy subjects was estimated to be 275 L (17%). In vitro plasma protein binding of quizartinib and AC886 is 99% or greater. In vitro blood-to-plasma ratio for quizartinib and AC886 ranges from 0.79-1.30 and 1.36-3.19, respectively. Elimination Total body clearance of quizartinib in healthy subjects was estimated to be 2.23 L/hour (29%). The mean (SD) effective half-lives (t 1/2 ) in patients with newly diagnosed AML for quizartinib and AC886 during maintenance therapy are 81 hours (±73) and 136 hours (±113), respectively. Metabolism In vitro quizartinib is primarily metabolized via oxidation by CYP3A4/5 and AC886 is formed and metabolized by CYP3A4/5. Excretion Following a single radiolabeled dose of quizartinib 53 mg to healthy subjects, 76.3% of the total radioactivity was recovered in feces (4% unchanged) and 1.64% in urine. Specific Populations There were no clinically significant differences in the exposure of quizartinib and AC886 based on age (range 18 to 91 years), sex, race (White 65%, Asian 18%, Black 9%), or body weight (range 37 to 153 kg). Patients with Renal Impairment Mild or moderate renal impairment (i.e., estimated creatinine clearance [CLcr] by Cockcroft-Gault equation: 30 to 89 mL/min) were not associated with clinically significant differences in the exposure of quizartinib and AC886. The impact of severe renal impairment (CLcr <30 mL/min) on the pharmacokinetics of quizartinib and AC886 is unknown [see Use in Specific Populations (8.6) ] . Patients with Hepatic Impairment Mild (total bilirubin ≤ upper limit of normal [ULN] and aspartate aminotransferase [AST] >ULN or total bilirubin >1 to 1.5 times ULN and any value for AST) or moderate (total bilirubin >1.5 to 3 times ULN and any value for AST) hepatic impairment were not associated with clinically significant differences in the exposure of quizartinib and AC886. The impact of severe hepatic impairment (Child-Pugh Class C or total bilirubin >3 times ULN and any value for AST) on the pharmacokinetics of quizartinib and AC886 is unknown [see Use in Specific Populations (8.7) ] . Drug Interaction Studies and Model-Informed Approaches Clinical Studies Strong CYP3A Inhibitors The AUC of quizartinib increased by 94% and the C max by 17% following coadministration of a single 53 mg quizartinib dose with ketoconazole (a strong CYP3A inhibitor). The AUCinf of AC886 decreased by 94% and C max by 60%. Moderate CYP3A Inhibitors A clinically significant change in quizartinib and AC886 exposure (C max and AUC inf ) was not observed following coadministration of a single quizartinib dose with fluconazole (a moderate CYP3A inhibitor). Strong or Moderate CYP3A Inducers The AUC inf of quizartinib decreased by 90% and C max by 45% following concomitant use of a single 53 mg dose of quizartinib with efavirenz (a moderate CYP3A inducer). The AUC of AC886 decreased by 96% and the C max by 68%. The effect of concomitant use with a strong CYP3A inducer may result in even greater effect on quizartinib pharmacokinetics based on mechanistic understanding of the drugs involved. Gastric Acid Reducing Agents No clinically significant differences in quizartinib pharmacokinetics were observed when used concomitantly with lansoprazole (a proton pump inhibitor that reduces gastric acid). Other Drugs There were no clinically significant differences in the pharmacokinetics of P-gp substrates (dabigatran etexilate) or UGT1A1 substrates (raltegravir) when used concomitantly with quizartinib. In Vitro Studies Cytochrome P450 (CYP) Enzymes Quizartinib does not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4. Quizartinib does not induce CYP3A4, CYP1A2, or CYP2B6. AC886 does not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2D6, CYP2C19, or CYP3A4. AC886 does not induce CYP3A4, CYP1A2, or CYP2B6. Other Metabolic Pathways Quizartinib inhibits UGT1A1. Transporters Quizartinib is a substrate for P-gp but not for BCRP, OATP1B1, OATP1B3, OCT1, OAT2, MATE1, or MRP2. AC886 is a substrate for BCRP but not for OATP1B1, OATP1B3, MATE1, or MRP2. Quizartinib inhibits BCRP and inhibition of this transporter at the recommended dosage cannot be excluded."],"indications_and_usage":["1 INDICATIONS AND USAGE VANFLYTA is indicated in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-approved test [see Dosage and Administration (2.1) and Clinical Studies (14) ] . VANFLYTA is a kinase inhibitor indicated in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-approved test. ( 1 ) Limitations of Use: VANFLYTA is not indicated as maintenance monotherapy following allogeneic hematopoietic stem cell transplantation (HSCT); improvement in overall survival with VANFLYTA in this setting has not been demonstrated. ( 1 ) Limitations of Use VANFLYTA is not indicated as maintenance monotherapy following allogeneic hematopoietic stem cell transplantation (HSCT); improvement in overall survival with VANFLYTA in this setting has not been demonstrated [see Clinical Studies (14) ] ."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS QT Prolongation, Torsades de Pointes, and Cardiac Arrest: Monitor electrocardiograms and levels of serum electrolytes. Reduce, interrupt, or permanently discontinue VANFLYTA as appropriate. ( 2.3 , 5.1 ) Embryo-Fetal Toxicity: VANFLYTA can cause fetal harm. Advise females of reproductive potential and males with female partners of reproductive potential of potential risk to a fetus and to use effective contraception. ( 5.3 , 8.1 , 8.3 ) 5.1 QT Prolongation, Torsades de Pointes, and Cardiac Arrest VANFLYTA prolongs the QT interval in a dose- and concentration-dependent manner. The mechanism of QTc interval prolongation is via inhibition of the slow delayed rectifier potassium current, I Ks , as compared to all other medications that prolong the QTc interval, which is via the rapid delayed rectifier potassium current, I Kr . Therefore, the level of QTc prolongation with VANFLYTA that predicts the risk of cardiac arrhythmias is unclear. Inhibition of I Ks and I Kr may leave patients with limited reserve leading to a higher risk of QT prolongation and serious cardiac arrhythmias, including fatal outcomes [see Clinical Pharmacology (12.2) ] . Torsades de pointes, ventricular fibrillation, cardiac arrest, and sudden death have occurred in patients treated with VANFLYTA. Of the 1,081 patients with AML treated with VANFLYTA in clinical trials, torsades de pointes occurred in approximately 0.2% of patients, cardiac arrest occurred in 0.6%, including 0.4% with a fatal outcome, and 0.1% of patients experienced ventricular fibrillation [see Adverse Reactions (6.1) ] . These severe cardiac arrhythmias occurred predominantly during the induction phase. Of the 265 patients with newly diagnosed FLT3-ITD-positive AML treated with VANFLYTA in combination with chemotherapy in the clinical trial, 2.3% were found to have a QTcF greater than 500 ms and 10% of patients had an increase from baseline QTcF greater than 60 ms. The clinical trial excluded patients with a QTcF ≥450 ms or other factors that increased the risk of QT prolongation or arrhythmic events (e.g., NYHA Class III or IV congestive heart failure, hypokalemia, family history of long QT interval syndrome). Therefore, avoid use in patients who are at significant risk of developing torsades de pointes, including uncontrolled or significant cardiac disease, recent myocardial infarction, heart failure, unstable angina, bradyarrhythmias, tachyarrhythmias, uncontrolled hypertension, high-degree atrioventricular block, severe aortic stenosis, or uncontrolled hypothyroidism. Do not initiate treatment with VANFLYTA if the QTcF interval is greater than 450 ms. Do not use VANFLYTA in patients with severe hypokalemia, severe hypomagnesemia, long QT syndrome, or in patients with a history of ventricular arrhythmias or torsades de pointes [see Contraindications (4) ] . Perform an ECG and correct electrolyte abnormalities prior to initiation of treatment with VANFLYTA. During induction and consolidation, perform an ECG prior to initiation and then once weekly during VANFLYTA treatment or more frequently as clinically indicated. During maintenance, perform ECGs prior to initiation, once weekly for at least the first month following dose initiation and escalation, and as clinically indicated thereafter. Do not escalate the dose if QTcF is greater than 450 ms [see Dosage and Administration (2.3) ] . Perform ECG monitoring of the QT interval more frequently in patients who are at significant risk of developing QT interval prolongation and torsades de pointes, or following dose escalation. Monitor and correct hypokalemia and hypomagnesemia prior to and during treatment with VANFLYTA. Maintain electrolytes in the normal range. Monitor electrolytes and ECGs more frequently in patients who experience diarrhea or vomiting. Monitor patients more frequently with ECGs if coadministration of VANFLYTA with drugs known to prolong the QT interval is required [see Drug Interactions (7) ] . Reduce the VANFLYTA dose when used concomitantly with strong CYP3A inhibitors, as they may increase quizartinib exposure [see Dosage and Administration (2.4) ] . Reduce VANFLYTA if QTc increases to greater than 480 ms and less than 500 ms. Interrupt and reduce VANFLYTA if QTc increases to greater than 500 ms. Permanently discontinue VANFLYTA in patients who develop recurrent QTc greater than 500 ms or QTc interval prolongation with signs or symptoms of life-threatening arrhythmia [see Dosage and Administration (2.3) ] . VANFLYTA is available only through a restricted program under a REMS [see Warnings and Precautions (5.2) ] . 5.2 VANFLYTA REMS VANFLYTA is available only through a restricted distribution program under a REMS called the VANFLYTA REMS because of the serious risk of QT prolongation, torsades de pointes, and cardiac arrest [see Warnings and Precautions (5.1) ] . Notable requirements of the VANFLYTA REMS include the following: Prescribers must be certified in the VANFLYTA REMS by enrolling and completing training. Prescribers must counsel patients receiving VANFLYTA about the risk of QT prolongation, torsades de pointes, and cardiac arrest, and provide patients with a Patient Wallet Card. Pharmacies that dispense VANFLYTA must be certified with the VANFLYTA REMS and must verify prescribers are certified through the VANFLYTA REMS. Further information about the VANFLYTA REMS is available at www.VANFLYTAREMS.com or by telephone at 1-855-212-6670. 5.3 Embryo-Fetal Toxicity Based on findings in animals and its mechanism of action, VANFLYTA can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, administration of quizartinib to pregnant rats during organogenesis at exposures 3 times the maximum recommended human dose (MRHD) of 53 mg/day caused structural abnormalities and alterations to growth. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with VANFLYTA and for 7 months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with VANFLYTA and for 4 months after the last dose [see Use in Specific Populations (8.1 , 8.3) ] ."],"clinical_studies_table":["
Figure 1: Kaplan-Meier Curve for Overall Survival in QuANTUM-First
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenicity studies have not been conducted with quizartinib. Quizartinib was mutagenic in a bacterial reverse mutation (Ames) assay and not mutagenic in an in vivo transgenic rat mutation assay. Quizartinib was not genotoxic in vitro in mouse lymphoma thymidine kinase mutation and human lymphocyte chromosome aberration assays, or in an in vivo rat bone marrow micronucleus assay. Fertility studies in animals have not been conducted with quizartinib. However, adverse findings in male and female reproductive systems were observed in repeat-dose toxicity studies in rats and monkeys. Findings in female animals (rats or monkeys) included ovarian cysts, vaginal mucosal modifications, and atrophy of the uterus, ovary, and vagina, starting at exposures (AUC) approximately 0.2 times the MRHD of 53 mg/day. In male animals (rats and monkeys), findings included testicular seminiferous tubular degeneration, failure of sperm release, germ cell depletion in the testes, and oligospermia/aspermia, starting at exposures approximately 0.4 times the MRHD. After approximately one month of recovery period, all these findings except the vaginal mucosal modifications in the female rats were reversible."],"pharmacokinetics_table":["
Table 8: Pharmacokinetic Properties of Quizartinib and AC886
QuizartinibAC886
General Information
Steady state exposure following 35.4 mg VANFLYTA once daily during induction therapy in patients with newly diagnosed AML
Cmax140 ng/mL (71%)163 ng/mL (52%)
AUC0-24h2,680 ng∙h/mL (85%)3,590 ng∙h/mL (51%)
Steady state exposure following 35.4 mg VANFLYTA once daily during consolidation therapy in patients with newly diagnosed AML
Cmax204 ng/mL (64%)172 ng/mL (47%)
AUC0-24h3,930 ng∙h/mL (78%)3,800 ng∙h/mL (46%)
Steady state exposure following 53 mg VANFLYTA once daily during maintenance therapy in patients with newly diagnosed AML
Cmax529 ng/mL (60%)262 ng/mL (48%)
AUC0-24h10,200 ng∙h/mL (75%)5,790 ng∙h/mL (46%)
Accumulation ratioMean (±SD) (AUC0-24h) 5.4 (4.4)8.7 (6.8)
"],"adverse_reactions_table":["
Table 5: Adverse Reactions (≥10%) in Patients with Newly Diagnosed FLT3-ITD positive AML Who Received VANFLYTA (with a Difference Between Arms of ≥2% Compared to Placebo) in the Clinical Trial
Body System Adverse ReactionVANFLYTA + Chemotherapy (N=265)PLACEBO + Chemotherapy (N=268)
All Grades %Grade 3 or 4 %All Grades %Grade 3 or 4 %
Blood and Lymphatic System Disorders
Febrile neutropeniaIncluding fatalities.44434241
NeutropeniaIncludes other related terms.29261412
Thrombocytopenia18131312
Anemia11675
Gastrointestinal Disorders
DiarrheaDiarrhea includes colitis, diarrhea, enteritis, enterocolitis, gastroenteritis, and neutropenic colitis.428398
MucositisMucositis includes anal inflammation, anal ulcer, anorectal discomfort, aphthous ulcer, laryngeal inflammation, laryngeal pain, mucosal inflammation, edema mucosal, esophageal pain, esophageal ulcer, esophagitis, oral blood blister, oral disorder, oral mucosa erosion, oral mucosal blistering, oral mucosal erythema, oral pain, oropharyngeal pain, pharyngeal inflammation, proctalgia, proctitis, stomatitis, tongue ulceration, and vaginal ulceration.385334.1
Nausea341.5311.9
Abdominal pain302.3221.1
Vomiting250201.5
Dyspepsia110.490.7
Infections and Infestations
SepsisSepsis includes acinetobacter infection, bacteremia, bacterial sepsis, corynebacterium bacteremia, device related bacteremia, device related sepsis, enterobacter sepsis, enterococcal bacteremia, enterococcal sepsis, escherichia bacteremia, escherichia sepsis, klebsiella bacteremia, klebsiella sepsis, neutropenic sepsis, pseudomonal bacteremia, pulmonary sepsis, sepsis, septic shock, staphylococcal bacteremia, staphylococcal infection, staphylococcal sepsis, stenotrophomonas sepsis, streptococcal sepsis, and streptococcal bacteremia.,30192620
Upper respiratory tract infection212.6123
Fungal infectionFungal infection includes aspergillosis oral, aspergillus infection, bronchopulmonary aspergillosis, candida infection, candida sepsis, fungal infection, fungal sepsis, fungal skin infection, fusarium infection, gastrointestinal candidiasis, hepatic infection fungal, hepatosplenic candidiasis, lower respiratory tract infection fungal, mucormycosis, oral candidiasis, oral fungal infection, oropharyngeal candidiasis, systemic candida, systemic mycosis, tinea cruris, and vulvovaginal candidiasis.,166103
Herpesvirus infectionHerpesvirus infection includes disseminated varicella zoster virus infection, genital herpes, herpes simplex, herpesvirus infection, herpes zoster, oral herpes, and varicella zoster virus infection.142.681.9
Nervous System Disorders
Headache280200.7
Hepatobiliary disorders
HypertransaminasemiaHypertransaminasemia includes alanine aminotransferase increased, aspartate aminotransferase increased, transaminases increased, hepatic enzymes increased, and hypertransaminasemia.197146
Metabolism and Nutrition Disorders
Decreased appetite174.9131.9
Respiratory, Thoracic and Mediastinal Disorders
Epistaxis151.1110.4
Psychiatric Disorders
Insomnia140110
Investigations
Electrocardiogram QT prolonged1434.11.1
Eye Disorders
Eye irritationEye irritation includes dry eye, eye inflammation, eye irritation, eye pain, eye pruritus, foreign body sensation in eyes, keratitis, and ulcerative keratitis.11070
","
Table 6: Select Laboratory Abnormalities (≥10%) That Worsened from Baseline in Patients with Newly Diagnosed FLT3-ITD positive AML (with a Difference Between Arms of ≥2% Compared to Placebo) in the Clinical Trial
Laboratory AbnormalityVANFLYTA + ChemotherapyThe denominator used to calculate the rate varied from 199 to 260 in VANFLYTA + Chemotherapy and from 187 to 267 in PLACEBO + Chemotherapy based on the number of patients with a baseline value and at least one post-treatment value.PLACEBO + Chemotherapy
All Grades%Grades 3 or 4%All Grades%Grades 3 or 4%
Lymphocytes decreased60575551
Potassium decreased59225618
Albumin decreased531.6454.3
Phosphorus decreased52224819
Alkaline phosphatase increased511.6471.9
Magnesium decreased442421.1
Calcium decreased332.4271.6
Creatine phosphokinase increased262.570.5
Potassium increased151.2110.8
Magnesium increased142.891.2
Sodium increased130100.4
"],"drug_interactions_table":["
Table 7: Effect of Other Drugs on VANFLYTA
Strong CYP3A Inhibitors
Clinical ImpactVANFLYTA is a CYP3A substrate. Concomitant use of VANFLYTA with a strong CYP3A inhibitor increases quizartinib systemic exposure [see Clinical Pharmacology (12.3)], which may increase the risk of VANFLYTA adverse reactions.
Prevention or ManagementReduce the dosage of VANFLYTA [see Dosage and Administration (2.4)].
Strong or Moderate CYP3A Inducers
Clinical ImpactConcomitant use of VANFLYTA with strong or moderate CYP3A inducers decreases quizartinib systemic exposure [see Clinical Pharmacology (12.3)], which may reduce VANFLYTA efficacy.
Prevention or ManagementAvoid concomitant use of VANFLYTA with strong or moderate CYP3A inducers [see Clinical Pharmacology (12.3)].
QT Interval Prolonging Drugs
Clinical ImpactVANFLYTA prolongs the QT/QTc interval. Coadministration of VANFLYTA with other drugs that prolong the QT interval may further increase the incidence of QT prolongation [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.2)].
Prevention or ManagementMonitor patients more frequently with ECG if coadministration of VANFLYTA with drugs known to prolong the QT interval is required. Examples of QT prolonging drugs include but are not limited to antifungal azoles, ondansetron, granisetron, azithromycin, pentamidine, doxycycline, moxifloxacin, atovaquone, prochlorperazine, and tacrolimus.
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide). QT Prolongation, Torsades de Pointes, and Cardiac Arrest Inform patients of symptoms that may be associated with significant QTc interval prolongation including dizziness, lightheadedness, and fainting. Advise patients to report these symptoms and the use of all medications to their healthcare provider [see Warnings and Precautions (5.1) ]. VANFLYTA REMS VANFLYTA is available only through a restricted program called the VANFLYTA REMS. Inform patients that they will be given a VANFLYTA Patient Wallet Card that they should carry with them at all times and show to all of their healthcare providers. This card describes signs and symptoms related to QT prolongation/cardiac arrhythmia which, if experienced, should prompt the patient to immediately seek medical attention [see Warnings and Precautions (5.2) ] . Drug Interactions Advise patients to inform their healthcare providers of all concomitant medications, including over-the-counter medications, vitamins, and herbal products. Advise patients to avoid concomitant use of St. John's wort as it is a strong CYP3A inducer [see Drug Interactions (7) ]. Embryo-Fetal Toxicity and Use of Contraceptives Advise pregnant women of the potential risk to the fetus. Advise female patients of reproductive potential to use effective contraception during treatment with VANFLYTA and for 7 months after the last dose. Advise patients to notify their healthcare provider immediately in the event of a pregnancy or if pregnancy is suspected during VANFLYTA treatment. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with VANFLYTA and for 4 months after the last dose [see Warnings and Precautions (5.3) and Use in Specific Populations (8.1 , 8.3) ]. Infertility Advise females and males of reproductive potential that VANFLYTA may impair fertility [see Use in Specific Populations (8.3) and Nonclinical Toxicology (13.1) ] . Lactation Advise women not to breastfeed during treatment with VANFLYTA and for one month after the last dose [see Use in Specific Populations (8.2) ]. Dosing and Storage Instructions Advise patients that VANFLYTA should be taken once daily at approximately the same time each day and may be taken with or without food. Advise patients to swallow tablets whole. Advise patients not to cut, crush, or chew the tablets [see Dosage and Administration (2.2) ]. Instruct patients that if a dose of VANFLYTA is vomited, not to take an additional dose that day, and to wait until the next scheduled dose on the following day. If a dose of VANFLYTA is missed or not taken at the usual time, instruct patients to take the dose as soon as possible on the same day and return to the usual dosing schedule the following day. Store VANFLYTA at room temperature from 20°C to 25°C (68°F to 77°F)."],"spl_unclassified_section":["Manufactured for: Daiichi Sankyo, Inc., Basking Ridge, NJ 07920 VANFLYTA ® is a registered trademark of Daiichi Sankyo Company, Ltd. Copyright © 2024, Daiichi Sankyo, Inc. USPI-VAN-C2-0624-r002"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Take VANFLYTA tablets orally once daily with or without food at approximately the same time each day. ( 2.2 ) See Full Prescribing Information for recommended VANFLYTA dosage regimen and dosage modifications. ( 2.2 , 2.3 , 2.4 ) 2.1 Patient Selection Select patients for the treatment of AML with VANFLYTA based on the presence of FLT3-ITD mutation positivity [see Clinical Studies (14) ] . Information on FDA-approved tests for the detection of FLT3-ITD mutation in AML is available at: http://www.fda.gov/CompanionDiagnostics. 2.2 Recommended Dosage A treatment course consists of up to 2 cycles of VANFLYTA in combination with induction cytarabine and anthracycline, up to 4 cycles of VANFLYTA in combination with high-dose cytarabine consolidation, and up to 36 cycles of VANFLYTA as maintenance therapy [see Clinical Studies (14) ] or until disease progression or unacceptable toxicity. VANFLYTA maintenance therapy should be initiated following consolidation chemotherapy upon blood count recovery of absolute neutrophil count >500/mm 3 and platelet count >50,000/mm 3 . See Table 1 for the recommended dosage of VANFLYTA by phase of therapy . Table 1: VANFLYTA Dosage Regimen VANFLYTA Initiation Induction Patients can receive up to 2 cycles of induction. Consolidation Patients can receive up to 4 cycles of consolidation. Maintenance Starting on Day 8 (for 7 + 3 regimen) For 5 + 2 regimen as the second induction cycle, VANFLYTA will be given on Days 6 to 19. Starting on Day 6 Starting on Day 1 Dose 35.4 mg orally once daily 35.4 mg orally once daily Administer 26.5 mg orally once daily Days 1 through 14 of the first cycle if QTcF is less than or equal to 450 ms. Increase the dose to 53 mg once daily on Day 15 of the first cycle if QTcF is less than or equal to 450 ms. Maintain the 26.5 mg once daily dose if QTcF greater than 500 ms was observed during induction or consolidation. Duration (28-day cycles) Two weeks in each cycle (Days 8 to 21) Two weeks in each cycle (Days 6 to 19) Once daily with no break between cycles for up to 36 cycles For patients who proceed to hematopoietic stem cell transplantation (HSCT), VANFLYTA should be stopped 7 days before the start of a conditioning regimen. Administer VANFLYTA orally with or without food at approximately the same time each day. Swallow tablets whole. Do not cut, crush, or chew the tablets. If a dose of VANFLYTA is vomited, do not administer a replacement dose; wait until the next scheduled dose is due. If a dose of VANFLYTA is missed or not taken at the usual time, administer the dose as soon as possible on the same day and return to the usual schedule the following day. The patient should not take two doses on the same day. 2.3 Monitoring and Dosage Modifications for Adverse Reactions Initiate VANFLYTA only if QTcF is less than or equal to 450 ms [see Warnings and Precautions (5.1) ]. During induction and consolidation, perform ECGs prior to initiation and then once weekly during VANFLYTA treatment or more frequently as clinically indicated [see Warnings and Precautions (5.1) ]. During maintenance, perform ECGs prior to initiation, once weekly for at least the first month following dose initiation and escalation, and thereafter as clinically indicated. Escalate the dose only if QTcF is less than or equal to 450 ms [see Dosage and Administration (2.2) and Warnings and Precautions (5.1) ]. Correct electrolyte abnormalities (hypokalemia and hypomagnesemia), and if possible, avoid concomitant administration of drugs that prolong the QT interval [see Warnings and Precautions (5.1) ]. For recommended dosage modifications due to adverse reactions, see Table 2 . For dosage adjustments due to adverse reactions, see Table 3 . Table 2: Recommended Dosage Modifications for Adverse Reactions [see Warnings and Precautions (5.1) and Adverse Reactions (6.1) ] Adverse Reaction Recommended Action Grades are in accordance with National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03 (NCI CTCAE v4.03). QTcF between 450 ms and 480 ms (Grade 1) Continue VANFLYTA dose. QTcF between 481 ms and 500 ms (Grade 2) Reduce the dose of VANFLYTA (see Table 3 ) without interruption. Resume VANFLYTA at the previous dose in the next cycle if QTcF has decreased to less than 450 ms. Monitor the patient closely for QT prolongation during the first cycle at the increased dose. QTcF greater than 500 ms (Grade 3) Interrupt VANFLYTA. Resume VANFLYTA at a reduced dose (see Table 3 ) when QTcF returns to less than 450 ms. Maintain the 26.5 mg once daily dose during maintenance if QTcF greater than 500 ms was observed during induction or consolidation. Recurrent QTcF greater than 500 ms (Grade 3) Permanently discontinue VANFLYTA if QTcF greater than 500 ms recurs despite appropriate dose reduction and correction/elimination of other risk factors (e.g., serum electrolyte abnormalities, concomitant QT prolonging medications). Torsades de pointes, polymorphic ventricular tachycardia, signs/symptoms of life-threatening arrhythmia (Grade 4) Permanently discontinue VANFLYTA. Grade 3 or 4 non-hematologic adverse reactions Interrupt VANFLYTA. Resume treatment at the previous dose if adverse reaction improves to Grade 1 or less. Resume treatment at a reduced dose (see Table 3 ) if adverse reaction improves to Grade 2. Discontinue if Grade 3 or 4 adverse reaction persists beyond 28 days. Grade 3 or 4 hypokalemia (<3 mmol/L) or hypomagnesemia (<0.4 mmol/L or <0.9 mg/dL) Interrupt VANFLYTA. Correct hypokalemia and hypomagnesemia according to institutional guidelines. VANFLYTA may be restarted at the previous dose when the adverse reaction improves to Grade 2 or less without symptoms. Grade 4 neutropenia or thrombocytopenia after achieving remission Recommend bone marrow evaluation. Reduce VANFLYTA dose (see Table 3 ). Table 3: Recommended Dosage Adjustments for Adverse Reactions for VANFLYTA Current Dosage Modified Dosage 53 mg once daily 35.4 mg once daily 35.4 mg once daily 26.5 mg once daily 26.5 mg once daily Interrupt 17.7 mg once daily Interrupt 2.4 Dosage Modifications for Strong CYP3A Inhibitors Reduce the dosage of VANFLYTA when used concomitantly with strong CYP3A inhibitors as shown in Table 4. If the current dosage is 17.7 mg once daily, interrupt VANFLYTA treatment for the duration of strong CYP3A inhibitor use. After discontinuation of a strong CYP3A inhibitor for 5 half-lives, resume the VANFLYTA dose that was taken before initiating the strong inhibitor [see Drug Interactions (7) ] . Table 4: Dosage Adjustments for Concomitant Use with Strong CYP3A Inhibitors Current Dosage Modified Dosage 53 mg once daily 26.5 mg once daily 35.4 mg once daily 17.7 mg once daily 26.5 mg once daily 17.7 mg once daily"],"spl_product_data_elements":["VANFLYTA QUIZARTINIB QUIZARTINIB DIHYDROCHLORIDE QUIZARTINIB HYDROXYPROPYL BETADEX MICROCRYSTALLINE CELLULOSE HYPROMELLOSE, UNSPECIFIED MAGNESIUM STEARATE TALC TRIACETIN TITANIUM DIOXIDE DSC;511 VANFLYTA QUIZARTINIB QUIZARTINIB DIHYDROCHLORIDE QUIZARTINIB HYDROXYPROPYL BETADEX MICROCRYSTALLINE CELLULOSE HYPROMELLOSE, UNSPECIFIED MAGNESIUM STEARATE TALC TRIACETIN TITANIUM DIOXIDE FERRIC OXIDE YELLOW DSC;512"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Tablets: 17.7 mg quizartinib, white, round, film-coated, debossed with \"DSC511\" 26.5 mg quizartinib, yellow, round, film-coated, debossed with \"DSC512\" Tablets: 17.7 mg or 26.5 mg. ( 3 )"],"storage_and_handling_table":["
Tablet StrengthTablet DescriptionPackage ConfigurationNDC
17.7 mgWhite, round, film-coated, debossed with "DSC511",28-count bottle65597-504-28
14-count bottle65597-504-04
26.5 mgYellow, round, film-coated, debossed with "DSC512"28-count bottle65597-511-28
14-count bottle65597-511-04
"],"clinical_pharmacology_table":["
Table 8: Pharmacokinetic Properties of Quizartinib and AC886
QuizartinibAC886
General Information
Steady state exposure following 35.4 mg VANFLYTA once daily during induction therapy in patients with newly diagnosed AML
Cmax140 ng/mL (71%)163 ng/mL (52%)
AUC0-24h2,680 ng∙h/mL (85%)3,590 ng∙h/mL (51%)
Steady state exposure following 35.4 mg VANFLYTA once daily during consolidation therapy in patients with newly diagnosed AML
Cmax204 ng/mL (64%)172 ng/mL (47%)
AUC0-24h3,930 ng∙h/mL (78%)3,800 ng∙h/mL (46%)
Steady state exposure following 53 mg VANFLYTA once daily during maintenance therapy in patients with newly diagnosed AML
Cmax529 ng/mL (60%)262 ng/mL (48%)
AUC0-24h10,200 ng∙h/mL (75%)5,790 ng∙h/mL (46%)
Accumulation ratioMean (±SD) (AUC0-24h) 5.4 (4.4)8.7 (6.8)
"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Lactation: Advise not to breastfeed. ( 8.2 ) 8.1 Pregnancy Risk Summary Based on findings from animal studies and its mechanism of action, VANFLYTA can cause embryo-fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1) ] . There are no available data on VANFLYTA use in pregnant women to evaluate for a drug-associated risk. In animal reproduction studies, oral administration of quizartinib to pregnant rats during organogenesis resulted in adverse developmental outcomes including structural abnormalities and alterations to growth at maternal exposures approximately 3 times those in patients at the maximum recommended human dose (MRHD) of 53 mg/day ( see Data ). Advise pregnant women of the potential risk to a fetus. The background risk in the U.S. general population of major birth defects is 2-4%, and of miscarriage is 15-20% of clinically recognized pregnancies. Data Animal Data In an embryo-fetal development study in rats, pregnant animals received oral doses of quizartinib of 0, 0.6, 2, or 6 mg/kg/day during the period of organogenesis. Administration of quizartinib at the dose of 6 mg/kg/day was associated with adverse developmental outcomes including structural abnormalities (anasarca and edema) and alterations to growth (lower fetal weights and effects on skeletal ossification). At this dose, the maternal systemic exposures (AUC) were approximately 3 times the human exposure at the MRHD of 53 mg/day. 8.2 Lactation Risk Summary There are no data on the presence of quizartinib or its metabolites in human milk, or the effects on the breastfed child or milk production. Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during treatment with VANFLYTA and for one month after the last dose. 8.3 Females and Males of Reproductive Potential VANFLYTA can cause embryo-fetal harm when administered to pregnant women [see Use in Specific Populations (8.1) ] . Pregnancy Testing Verify pregnancy status in females of reproductive potential within seven days before starting treatment with VANFLYTA. Contraception Females Advise female patients of reproductive potential to use effective contraception during treatment with VANFLYTA and for 7 months after the last dose. Males Based on genotoxicity findings, advise male patients with female partners of reproductive potential to use effective contraception during treatment with VANFLYTA and for 4 months after the last dose [see Nonclinical Toxicology (13.1) ] . Infertility Females Based on findings from animal studies, VANFLYTA may impair female fertility. These effects on fertility were reversible [see Nonclinical Toxicology (13.1) ] . Males Based on findings from animal studies, VANFLYTA may impair male fertility. These effects on fertility were reversible [see Nonclinical Toxicology (13.1) ]. 8.4 Pediatric Use Safety and effectiveness of VANFLYTA have not been established in pediatric patients. 8.5 Geriatric Use There were 533 patients with newly diagnosed AML in the clinical study; of the total number of VANFLYTA-treated patients, 69 (26%) were 65 years of age and older, while 1 (0.4%) was 75 years of age [see Clinical Studies (14) ] . No overall differences in safety or efficacy were observed between patients 65 years of age and older and younger adult patients. 8.6 Renal Impairment No dosage adjustment is recommended in patients with mild to moderate renal impairment (i.e., estimated creatinine clearance [CLcr] by Cockcroft-Gault equation: CLcr 30 to 89 mL/min). VANFLYTA has not been studied in patients with severe renal impairment (CLcr <30 mL/min) [see Clinical Pharmacology (12.3) ] . 8.7 Hepatic Impairment No dosage adjustment is recommended in patients with mild hepatic impairment (Child-Pugh Class A or total bilirubin ≤ upper limit of normal [ULN] and aspartate aminotransferase [AST] >ULN, or total bilirubin >1 to 1.5 times ULN and any value for AST) or moderate hepatic impairment (Child-Pugh Class B or total bilirubin >1.5 to 3 times ULN and any value for AST). VANFLYTA has not been studied in patients with severe (Child-Pugh Class C or total bilirubin >3 times ULN and any value for AST) hepatic impairment [see Clinical Pharmacology (12.3) ] ."],"dosage_and_administration_table":["
Table 1: VANFLYTA Dosage Regimen
VANFLYTA InitiationInductionPatients can receive up to 2 cycles of induction.ConsolidationPatients can receive up to 4 cycles of consolidation.Maintenance
Starting on Day 8 (for 7 + 3 regimen)For 5 + 2 regimen as the second induction cycle, VANFLYTA will be given on Days 6 to 19.Starting on Day 6Starting on Day 1
Dose35.4 mg orally once daily35.4 mg orally once dailyAdminister 26.5 mg orally once daily Days 1 through 14 of the first cycle if QTcF is less than or equal to 450 ms.Increase the dose to 53 mg once daily on Day 15 of the first cycle if QTcF is less than or equal to 450 ms. Maintain the 26.5 mg once daily dose if QTcF greater than 500 ms was observed during induction or consolidation.
Duration (28-day cycles)Two weeks in each cycle (Days 8 to 21)Two weeks in each cycle (Days 6 to 19)Once daily with no break between cycles for up to 36 cycles
","
Table 2: Recommended Dosage Modifications for Adverse Reactions [see Warnings and Precautions (5.1) and Adverse Reactions (6.1)]
Adverse ReactionRecommended Action
Grades are in accordance with National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03 (NCI CTCAE v4.03).
QTcF between 450 ms and 480 ms (Grade 1)Continue VANFLYTA dose.
QTcF between 481 ms and 500 ms (Grade 2)Reduce the dose of VANFLYTA (see Table 3) without interruption.Resume VANFLYTA at the previous dose in the next cycle if QTcF has decreased to less than 450 ms. Monitor the patient closely for QT prolongation during the first cycle at the increased dose.
QTcF greater than 500 ms (Grade 3)Interrupt VANFLYTA.Resume VANFLYTA at a reduced dose (see Table 3) when QTcF returns to less than 450 ms.Maintain the 26.5 mg once daily dose during maintenance if QTcF greater than 500 ms was observed during induction or consolidation.
Recurrent QTcF greater than 500 ms (Grade 3)Permanently discontinue VANFLYTA if QTcF greater than 500 ms recurs despite appropriate dose reduction and correction/elimination of other risk factors (e.g., serum electrolyte abnormalities, concomitant QT prolonging medications).
Torsades de pointes, polymorphic ventricular tachycardia, signs/symptoms of life-threatening arrhythmia (Grade 4)Permanently discontinue VANFLYTA.
Grade 3 or 4 non-hematologic adverse reactionsInterrupt VANFLYTA.Resume treatment at the previous dose if adverse reaction improves to Grade 1 or less.Resume treatment at a reduced dose (see Table 3) if adverse reaction improves to Grade 2.Discontinue if Grade 3 or 4 adverse reaction persists beyond 28 days.
Grade 3 or 4 hypokalemia (<3 mmol/L) or hypomagnesemia (<0.4 mmol/L or <0.9 mg/dL)Interrupt VANFLYTA.Correct hypokalemia and hypomagnesemia according to institutional guidelines.VANFLYTA may be restarted at the previous dose when the adverse reaction improves to Grade 2 or less without symptoms.
Grade 4 neutropenia or thrombocytopenia after achieving remissionRecommend bone marrow evaluation.Reduce VANFLYTA dose (see Table 3).
","
Table 3: Recommended Dosage Adjustments for Adverse Reactions for VANFLYTA
Current DosageModified Dosage
53 mg once daily35.4 mg once daily
35.4 mg once daily26.5 mg once daily
26.5 mg once dailyInterrupt
17.7 mg once dailyInterrupt
","
Table 4: Dosage Adjustments for Concomitant Use with Strong CYP3A Inhibitors
Current DosageModified Dosage
53 mg once daily26.5 mg once daily
35.4 mg once daily17.7 mg once daily
26.5 mg once daily17.7 mg once daily
"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 17.7 mg Tablet Bottle Carton NDC 65597-504-04 14 tablets VANFLYTA ® (quizartinib) tablets 17.7 mg Rx only Swallow tablets whole. Do not cut, crush, or chew the tablets. Dispense accompanying Medication Guide to each patient. Daiichi-Sankyo PRINCIPAL DISPLAY PANEL - 17.7 mg Tablet Bottle Carton","PRINCIPAL DISPLAY PANEL - 26.5 mg Tablet Bottle Carton NDC 65597-511-04 14 tablets VANFLYTA ® (quizartinib) tablets 26.5 mg Rx only Swallow tablets whole. Do not cut, crush, or chew the tablets. Dispense accompanying Medication Guide to each patient. Daiichi-Sankyo PRINCIPAL DISPLAY PANEL - 26.5 mg Tablet Bottle Carton"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenicity studies have not been conducted with quizartinib. Quizartinib was mutagenic in a bacterial reverse mutation (Ames) assay and not mutagenic in an in vivo transgenic rat mutation assay. Quizartinib was not genotoxic in vitro in mouse lymphoma thymidine kinase mutation and human lymphocyte chromosome aberration assays, or in an in vivo rat bone marrow micronucleus assay. Fertility studies in animals have not been conducted with quizartinib. However, adverse findings in male and female reproductive systems were observed in repeat-dose toxicity studies in rats and monkeys. Findings in female animals (rats or monkeys) included ovarian cysts, vaginal mucosal modifications, and atrophy of the uterus, ovary, and vagina, starting at exposures (AUC) approximately 0.2 times the MRHD of 53 mg/day. In male animals (rats and monkeys), findings included testicular seminiferous tubular degeneration, failure of sperm release, germ cell depletion in the testes, and oligospermia/aspermia, starting at exposures approximately 0.4 times the MRHD. After approximately one month of recovery period, all these findings except the vaginal mucosal modifications in the female rats were reversible."]},"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Macrophage colony-stimulating factor 1 receptor","category":"target"},{"label":"CSF1R","category":"gene"},{"label":"KIT","category":"gene"},{"label":"PDGFRA","category":"gene"},{"label":"L01EX11","category":"atc"},{"label":"Oral","category":"route"},{"label":"Tablet","category":"form"},{"label":"LOE Approaching","category":"status"},{"label":"Acute myeloid leukemia with FMS-like tyrosine kinase-3 mutation","category":"indication"},{"label":"Acute myeloid leukemia, disease","category":"indication"},{"label":"Daiichi Sankyo Inc","category":"company"},{"label":"Approved 2020s","category":"decade"}],"phase":"marketed","safety":{"boxedWarnings":["WARNING: QT PROLONGATION, TORSADES DE POINTES, and CARDIAC ARREST VANFLYTA prolongs the QT interval in a dose- and concentration-related manner [see Clinical Pharmacology (12.2) ] . Prior to VANFLYTA administration and periodically, monitor for hypokalemia or hypomagnesemia, and correct deficiencies. Perform ECGs to monitor the QTc at baseline, weekly during induction and consolidation therapy, weekly for at least the first month of maintenance, and periodically thereafter [see Dosage and Administration (2.3) and Warnings and Precautions (5.1) ]. Torsades de pointes and cardiac arrest have occurred in patients receiving VANFLYTA. Do not administer VANFLYTA to patients with severe hypokalemia, severe hypomagnesemia, or long QT syndrome [see Contraindications (4) and Warnings and Precautions (5.1) ] . Do not initiate treatment with VANFLYTA or escalate the VANFLYTA dose if the QT interval corrected by Fridericia's formula (QTcF) is greater than 450 ms [see Dosage and Administration (2.3) and Warnings and Precautions (5.1) ] . Monitor ECGs more frequently if concomitant use of drugs known to prolong the QT interval is required [see Dosage and Administration (2.3) and Warnings and Precautions (5.1) ] . Reduce the VANFLYTA dose when used concomitantly with strong CYP3A inhibitors, as they may increase quizartinib exposure [see Dosage and Administration (2.4) and Warnings and Precautions (5.1) ] . Because of the risk of QT prolongation, VANFLYTA is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the VANFLYTA REMS [see Warnings and Precautions (5.2) ] . WARNING: QT PROLONGATION, TORSADES DE POINTES, and CARDIAC ARREST See full prescribing information for complete boxed warning. VANFLYTA prolongs the QT interval. ( 12.2 ) Prior to VANFLYTA administration and periodically, perform electrocardiograms (ECGs), monitor for hypokalemia or hypomagnesemia, and correct deficiencies. ( 2.3 , 5.1 ) Torsades de pointes and cardiac arrest have occurred in patients receiving VANFLYTA. Do not administer VANFLYTA to patients with severe hypokalemia, severe hypomagnesemia, or long QT syndrome. ( 4 , 5.1 ) Do not initiate treatment with VANFLYTA or escalate the VANFLYTA dose if the QT interval corrected by Fridericia's formula (QTcF) is greater than 450 ms. ( 2.3 , 5.1 ) Monitor ECGs more frequently if concomitant use of drugs known to prolong the QT interval is required. ( 2.3 , 5.1 ) Reduce the VANFLYTA dose when used concomitantly with strong CYP3A inhibitors, as they may increase quizartinib exposure. ( 2.4 , 5.1 ) VANFLYTA is available only through a restricted program called the VANFLYTA Risk Evaluation and Mitigation Strategy (REMS). ( 5.2 )"],"safetySignals":[{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"54 reports"},{"date":"","signal":"NO ADVERSE EVENT","source":"FDA FAERS","actionTaken":"46 reports"},{"date":"","signal":"DEATH","source":"FDA FAERS","actionTaken":"44 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"35 reports"},{"date":"","signal":"PLATELET COUNT DECREASED","source":"FDA FAERS","actionTaken":"33 reports"},{"date":"","signal":"PYREXIA","source":"FDA FAERS","actionTaken":"28 reports"},{"date":"","signal":"FEBRILE NEUTROPENIA","source":"FDA FAERS","actionTaken":"25 reports"},{"date":"","signal":"ELECTROCARDIOGRAM QT PROLONGED","source":"FDA FAERS","actionTaken":"24 reports"},{"date":"","signal":"INFECTION","source":"FDA FAERS","actionTaken":"24 reports"},{"date":"","signal":"DISEASE PROGRESSION","source":"FDA FAERS","actionTaken":"23 reports"}],"drugInteractions":[{"drug":"Strong CYP3A Inhibitors","severity":"major","mechanism":"Concomitant use of VANFLYTA with a strong CYP3A inhibitor increases quizartinib systemic exposure","management":"Reduce the dosage of VANFLYTA","clinicalEffect":"May increase the risk of VANFLYTA adverse reactions"},{"drug":"Strong or Moderate CYP3A Inducers","severity":"major","mechanism":"Concomitant use of VANFLYTA with strong or moderate CYP3A inducers decreases quizartinib systemic exposure","management":"Avoid concomitant use of VANFLYTA with strong or moderate CYP3A inducers","clinicalEffect":"May reduce VANFLYTA efficacy"},{"drug":"QT Interval Prolonging Drugs","severity":"major","mechanism":"Coadministration of VANFLYTA with other drugs that prolong the QT interval may further increase the incidence of QT prolongation","management":"Monitor patients more frequently with ECG if coadministration is required","clinicalEffect":"May further increase the incidence of QT prolongation"}],"commonSideEffects":[{"effect":"Febrile neutropenia","drugRate":"11%","severity":"serious","_validated":true},{"effect":"Thrombocytopenia","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Sepsis","drugRate":"5%","severity":"serious","_validated":true},{"effect":"Diarrhea","drugRate":"4.3%","severity":"common","_validated":true},{"effect":"Mucositis","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Nausea","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Abdominal pain","drugRate":"2.3%","severity":"common","_validated":true},{"effect":"Vomiting","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Upper respiratory tract infection","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Fungal infection","drugRate":"1.6%","severity":"common","_validated":true},{"effect":"Herpesvirus infection","drugRate":"reported","severity":"unknown"},{"effect":"Potassium decreased","drugRate":"reported","severity":"unknown"},{"effect":"Lymphocytes decreased","drugRate":"reported","severity":"unknown"},{"effect":"Albumin decreased","drugRate":"reported","severity":"unknown"},{"effect":"Phosphorus decreased","drugRate":"reported","severity":"unknown"},{"effect":"Alkaline phosphatase increased","drugRate":"reported","severity":"unknown"},{"effect":"Magnesium decreased","drugRate":"reported","severity":"unknown"}],"specialPopulations":{"Lactation":"Because of the potential for serious adverse reactions in breastfed child, advise women not to breastfeed during treatment with VANFLYTA and for one month after the last dose.","Pregnancy":"Based on findings from animal studies and its mechanism of action, VANFLYTA can cause embryo-fetal harm when administered to pregnant woman. There are no available data on VANFLYTA use in pregnant women to evaluate for drug-associated risk. In animal reproduction studies, oral administration of quizartinib to pregnant rats during organogenesis resulted in adverse developmental outcomes including structural abnormalities and alterations to growth at maternal exposures approximately times those in patients at the maximum recommended human dose (MRHD) of 53 mg/day. Advise pregnant women of the potential risk to fetus.","Geriatric use":"No overall differences in safety or efficacy were observed between patients 65 years of age and older and younger adult patients.","Paediatric use":"Safety and effectiveness of VANFLYTA have not been established in pediatric patients."}},"trials":[],"aliases":[],"company":"Daiichi Sankyo Inc","patents":[{"applNo":"N216993","source":"FDA Orange Book","status":"Active","expires":"Mar 16, 2027","useCode":"U-3661","territory":"US","drugProduct":false,"patentNumber":"9585892","drugSubstance":false},{"applNo":"N216993","source":"FDA Orange Book","status":"Active","expires":"May 14, 2030","useCode":"U-3661","territory":"US","drugProduct":false,"patentNumber":"9555040","drugSubstance":false},{"applNo":"N216993","source":"FDA Orange Book","status":"Active","expires":"Mar 23, 2030","useCode":"U-3661","territory":"US","drugProduct":false,"patentNumber":"8836218","drugSubstance":false},{"applNo":"N216993","source":"FDA Orange Book","status":"Active","expires":"Feb 26, 2031","useCode":"U-3661","territory":"US","drugProduct":false,"patentNumber":"8357690","drugSubstance":false},{"applNo":"N216993","source":"FDA Orange Book","status":"Active","expires":"Mar 16, 2027","useCode":"U-3661","territory":"US","drugProduct":false,"patentNumber":"8129374","drugSubstance":false},{"applNo":"N216993","source":"FDA Orange Book","status":"Active","expires":"Aug 15, 2029","useCode":"U-3661","territory":"US","drugProduct":true,"patentNumber":"7968543","drugSubstance":false},{"applNo":"N216993","source":"FDA Orange Book","status":"Active","expires":"Aug 15, 2029","useCode":"","territory":"US","drugProduct":true,"patentNumber":"8865710","drugSubstance":false},{"applNo":"N216993","source":"FDA Orange Book","status":"Active","expires":"Mar 16, 2027","useCode":"","territory":"US","drugProduct":false,"patentNumber":"8883783","drugSubstance":true},{"applNo":"N216993","source":"FDA Orange Book","status":"Active","expires":"Sep 30, 2033","useCode":"","territory":"US","drugProduct":true,"patentNumber":"9675549","drugSubstance":false},{"applNo":"N216993","source":"FDA Orange Book","status":"Active","expires":"Mar 16, 2027","useCode":"","territory":"US","drugProduct":true,"patentNumber":"8557810","drugSubstance":false},{"applNo":"N216993","source":"FDA Orange Book","status":"Active","expires":"Sep 26, 2028","useCode":"","territory":"US","drugProduct":false,"patentNumber":"7820657","drugSubstance":true}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=QUIZARTINIB","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:48:01.647222+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T00:47:59.762084+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:48:07.727139+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:47:58.120670+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=QUIZARTINIB","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:48:08.045534+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:47:57.543286+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (boxed_warning)","rawText":"WARNING: QT PROLONGATION, TORSADES DE POINTES, and CARDIAC ARREST VANFLYTA prolongs the QT interval in a dose- and concentration-related manner [see Clinical Pharmacology (12.2) ] . Prior to VANFLYTA administration and periodically, monitor for hypokalemia or hypomagnesemia, and correct deficiencies. Perform ECGs to monitor the QTc at baseline, weekly during induction and consolidation therapy, weekly for at least the first month of maintenance, and periodically thereafter [see Dosage and Admini","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:47:57.543316+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:48:09.698727+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Tyrosine-protein kinase receptor RET inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:48:09.091943+00:00"},"safety.drugInteractions":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:48:28.887594+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL576982/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:48:08.752013+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA216993","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:47:57.543321+00:00"}},"allNames":"vanflyta","offLabel":[],"synonyms":["quizartinib","quizartinib hydrochloride","quizartinib dihydrochloride","vanflyta","AC220","AC010220"],"timeline":[{"date":"2019-06-18","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Daiichi Sankyo Company, Limited)"},{"date":"2023-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from DAIICHI SANKYO INC to Daiichi Sankyo Inc"},{"date":"2023-07-20","type":"positive","source":"DrugCentral","milestone":"FDA approval (Daiichi Sankyo Inc )"},{"date":"2027-03-16","type":"negative","source":"FDA Orange Book","milestone":"Substance patent 8883783 expires"},{"date":"2028-07-20","type":"negative","source":"FDA Orange Book","milestone":"New Chemical Entity exclusivity expires"},{"date":"2028-09-26","type":"negative","source":"FDA Orange Book","milestone":"Substance patent 7820657 expires"},{"date":"2030-07-20","type":"negative","source":"FDA Orange Book","milestone":"ODE-437 exclusivity expires"}],"aiSummary":"Vanflyta (quizartinib) is a small molecule therapy originally developed by Daiichi Sankyo Inc, currently owned by the same company. It targets the macrophage colony-stimulating factor 1 receptor and has been FDA-approved since 2023 for the treatment of acute myeloid leukemia with FMS-like tyrosine kinase-3 mutation and acute myeloid leukemia. Vanflyta is a patented medication with no generic manufacturers available. Key safety considerations include its potential side effects, which may require monitoring. Vanflyta is a promising treatment option for patients with specific types of acute myeloid leukemia.","approvals":[{"date":"2019-06-18","orphan":true,"company":"DAIICHI SANKYO COMPANY, LIMITED","regulator":"PMDA"},{"date":"2023-07-20","orphan":true,"company":"DAIICHI SANKYO INC ","regulator":"FDA"}],"brandName":"Vanflyta","ecosystem":[{"indication":"Acute myeloid leukemia with FMS-like tyrosine kinase-3 mutation","otherDrugs":[],"globalPrevalence":800000},{"indication":"Acute myeloid leukemia, disease","otherDrugs":[{"name":"aldesleukin","slug":"aldesleukin","company":"Chiron"},{"name":"azacitidine","slug":"azacitidine","company":"Celgene"},{"name":"cytarabine","slug":"cytarabine","company":""},{"name":"daunorubicin","slug":"daunorubicin","company":""}],"globalPrevalence":800000}],"mechanism":{"target":"Macrophage colony-stimulating factor 1 receptor","novelty":"Follow-on","targets":[{"gene":"CSF1R","source":"DrugCentral","target":"Macrophage colony-stimulating factor 1 receptor","protein":"Macrophage colony-stimulating factor 1 receptor"},{"gene":"KIT","source":"DrugCentral","target":"Mast/stem cell growth factor receptor Kit","protein":"Mast/stem cell growth factor receptor Kit"},{"gene":"PDGFRA","source":"DrugCentral","target":"Platelet-derived growth factor receptor alpha","protein":"Platelet-derived growth factor receptor alpha"},{"gene":"PDGFRB","source":"DrugCentral","target":"Platelet-derived growth factor receptor beta","protein":"Platelet-derived growth factor receptor beta"},{"gene":"RET","source":"DrugCentral","target":"Proto-oncogene tyrosine-protein kinase receptor Ret","protein":"Proto-oncogene tyrosine-protein kinase receptor Ret"},{"gene":"FLT3","source":"DrugCentral","target":"Receptor-type tyrosine-protein kinase FLT3","protein":"Receptor-type tyrosine-protein kinase FLT3"},{"gene":"FLT1","source":"DrugCentral","target":"Vascular endothelial growth factor receptor 1","protein":"Vascular endothelial growth factor receptor 1"},{"gene":"FLT4","source":"DrugCentral","target":"Vascular endothelial growth factor receptor 3","protein":"Vascular endothelial growth factor receptor 3"},{"gene":"DDR1","source":"DrugCentral","target":"Epithelial discoidin domain-containing receptor 1","protein":"Epithelial discoidin domain-containing receptor 1"},{"gene":"KDR","source":"DrugCentral","target":"Vascular endothelial growth factor receptor 2","protein":"Vascular endothelial growth factor receptor 2"}],"modality":"Small Molecule","explanation":"Quizartinib is small molecule inhibitor of the receptor tyrosine kinase FLT3. Quizartinib and its major active metabolite AC886 bind to the adenosine triphosphate (ATP) binding domain of FLT3 with comparable affinity, and both had 10-fold lower affinity towards FLT3-ITD mutation compared to FLT3 in binding assay. Quizartinib and AC886 inhibited FLT3 kinase activity, preventing autophosphorylation of the receptor, thereby inhibiting downstream FLT3 receptor signaling and blocking FLT3-ITD-dependent cell proliferation. Quizartinib showed antitumor activity in mouse model of FLT3-ITD-dependent leukemia.","oneSentence":"Vanflyta works by blocking the macrophage colony-stimulating factor 1 receptor, which is involved in the growth and survival of cancer cells.","technicalDetail":"Quizartinib is a potent and selective inhibitor of the macrophage colony-stimulating factor 1 receptor (CSF1R), a tyrosine kinase involved in the signaling pathways that regulate the growth, survival, and migration of tumor-associated macrophages and other immune cells."},"commercial":{"launchDate":"2023","_launchSource":"DrugCentral (FDA 2023-07-20, DAIICHI SANKYO INC )"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5341","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=QUIZARTINIB","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=QUIZARTINIB","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T15:32:11.751964","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:48:29.446859+00:00","fieldsConflicting":5,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"sunitinib","drugSlug":"sunitinib","fdaApproval":"2006-01-26","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"sorafenib","drugSlug":"sorafenib","fdaApproval":"2005-12-20","patentExpiry":"Sep 10, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"pazopanib","drugSlug":"pazopanib","fdaApproval":"2009-10-19","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"vandetanib","drugSlug":"vandetanib","fdaApproval":"2011-04-06","patentExpiry":"Aug 8, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"regorafenib","drugSlug":"regorafenib","fdaApproval":"2012-09-27","patentExpiry":"Jun 2, 2030","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"cabozantinib","drugSlug":"cabozantinib","fdaApproval":"2012-11-29","patentExpiry":"Oct 8, 2030","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"lenvatinib","drugSlug":"lenvatinib","fdaApproval":"2015-02-13","patentExpiry":"Sep 3, 2036","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"nintedanib","drugSlug":"nintedanib","fdaApproval":"2014-10-15","patentExpiry":"Jun 7, 2029","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"midostaurin","drugSlug":"midostaurin","fdaApproval":"2017-04-28","patentExpiry":"Oct 9, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"larotrectinib","drugSlug":"larotrectinib","fdaApproval":"2018-11-26","patentExpiry":"Oct 21, 2029","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"gilteritinib","drugSlug":"gilteritinib","fdaApproval":"2018-11-28","patentExpiry":"Nov 28, 2032","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"entrectinib","drugSlug":"entrectinib","fdaApproval":"2019-08-15","patentExpiry":"May 22, 2033","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"pexidartinib","drugSlug":"pexidartinib","fdaApproval":"2019-08-02","patentExpiry":"Nov 21, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"capmatinib","drugSlug":"capmatinib","fdaApproval":"2020-05-06","patentExpiry":"Nov 19, 2032","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"avapritinib","drugSlug":"avapritinib","fdaApproval":"2020-01-09","patentExpiry":"Oct 15, 2034","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"ripretinib","drugSlug":"ripretinib","fdaApproval":"2020-05-15","patentExpiry":"Oct 6, 2042","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"tepotinib","drugSlug":"tepotinib","fdaApproval":"2021-02-03","patentExpiry":"Oct 30, 2029","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"selpercatinib","drugSlug":"selpercatinib","fdaApproval":"2020-05-08","patentExpiry":"Oct 10, 2038","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"pralsetinib","drugSlug":"pralsetinib","fdaApproval":"2020-09-04","patentExpiry":"Nov 1, 2036","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"umbralisib","drugSlug":"umbralisib","fdaApproval":"2021-02-05","patentExpiry":"May 26, 2035","patentStatus":"Patent protected","relationship":"same-class"}],"exclusivity":[{"code":"NCE","date":"Jul 20, 2028"},{"code":"ODE-437","date":"Jul 20, 2030"},{"code":"NCE","date":"Jul 20, 2028"},{"code":"ODE-437","date":"Jul 20, 2030"}],"genericName":"quizartinib","indications":{"approved":[{"name":"Acute myeloid leukemia with FMS-like tyrosine kinase-3 mutation","source":"DrugCentral","snomedId":734522002,"regulator":"FDA","eligibility":{"age":"adult","stage":"newly diagnosed","biomarkers":"FLT3 internal tandem duplication (ITD)-positive","prior treatment":"standard cytarabine and anthracycline induction and cytarabine consolidation"},"prevalenceClass":"1-5 / 10 000","globalPrevalence":800000,"prevalenceMethod":"orphanet","prevalenceSource":"Orphanet (European Medicines Agency 2018[INST])"},{"name":"Acute myeloid leukemia, disease","source":"DrugCentral","snomedId":91861009,"regulator":"FDA","eligibility":{"age":"adult","stage":"newly diagnosed","biomarkers":"FLT3 internal tandem duplication (ITD)-positive","prior treatment":"standard cytarabine and anthracycline induction and cytarabine consolidation"},"usPrevalence":null,"globalPrevalence":800000,"prevalenceMethod":"curated","prevalenceSource":"Orphanet (European Medicines Agency 2018[INST])"}],"offLabel":[],"pipeline":[]},"currentOwner":"Daiichi Sankyo Inc","drugCategory":"loe-approaching","labelChanges":[],"relatedDrugs":[{"drugId":"sunitinib","brandName":"sunitinib","genericName":"sunitinib","approvalYear":"2006","relationship":"same-class"},{"drugId":"sorafenib","brandName":"sorafenib","genericName":"sorafenib","approvalYear":"2005","relationship":"same-class"},{"drugId":"pazopanib","brandName":"pazopanib","genericName":"pazopanib","approvalYear":"2009","relationship":"same-class"},{"drugId":"vandetanib","brandName":"vandetanib","genericName":"vandetanib","approvalYear":"2011","relationship":"same-class"},{"drugId":"regorafenib","brandName":"regorafenib","genericName":"regorafenib","approvalYear":"2012","relationship":"same-class"},{"drugId":"cabozantinib","brandName":"cabozantinib","genericName":"cabozantinib","approvalYear":"2012","relationship":"same-class"},{"drugId":"lenvatinib","brandName":"lenvatinib","genericName":"lenvatinib","approvalYear":"2015","relationship":"same-class"},{"drugId":"nintedanib","brandName":"nintedanib","genericName":"nintedanib","approvalYear":"2014","relationship":"same-class"},{"drugId":"midostaurin","brandName":"midostaurin","genericName":"midostaurin","approvalYear":"2017","relationship":"same-class"},{"drugId":"larotrectinib","brandName":"larotrectinib","genericName":"larotrectinib","approvalYear":"2018","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT04107727","phase":"PHASE2","title":"Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2019-09-05","conditions":["Acute Myeloid Leukemia"],"enrollment":273,"completionDate":"2025-01-24"},{"nctId":"NCT07478991","phase":"PHASE3","title":"Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)","status":"NOT_YET_RECRUITING","sponsor":"PETHEMA Foundation","startDate":"2026-03","conditions":["Acute Myeloid Leukemia, Adult"],"enrollment":376,"completionDate":"2030-04"},{"nctId":"NCT05735184","phase":"PHASE1","title":"A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML","status":"RECRUITING","sponsor":"Kura Oncology, Inc.","startDate":"2023-07-18","conditions":["Acute Myeloid Leukemia","Mixed Lineage Leukemia Gene Mutation","Refractory AML","AML With Mutated NPM1","Acute Myeloid Leukemia Recurrent","Acute Myeloid Leukemia, in Relapse","NPM1 Mutation","KMT2Ar","Myeloid Sarcoma","Nucleophosmin 1-mutated Acute Myeloid Leukemia"],"enrollment":420,"completionDate":"2030-04"},{"nctId":"NCT06578247","phase":"PHASE3","title":"Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2024-11-19","conditions":["Leukemia"],"enrollment":700,"completionDate":"2030-06-26"},{"nctId":"NCT07425808","phase":"PHASE2,PHASE3","title":"FLT3-ITD Targeted Therapy in Fit AML Patients","status":"NOT_YET_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2026-12-01","conditions":["AML (Acute Myeloid Leukemia)"],"enrollment":230,"completionDate":"2032-02-01"},{"nctId":"NCT06769490","phase":"PHASE1","title":"Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-07-10","conditions":["Acute Myeloid Leukemia"],"enrollment":44,"completionDate":"2030-09-15"},{"nctId":"NCT03661307","phase":"PHASE1,PHASE2","title":"Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-10-31","conditions":["Acute Myeloid Leukemia","Myelodysplastic Syndrome","Recurrent Acute Myeloid Leukemia","Recurrent Myelodysplastic Syndrome","Refractory Acute Myeloid Leukemia"],"enrollment":73,"completionDate":"2028-01-01"},{"nctId":"NCT04128748","phase":"PHASE1,PHASE2","title":"Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-05-27","conditions":["Acute Myeloid Leukemia","Blasts More Than 10 Percent of Bone Marrow Nucleated Cells","High Risk Myelodysplastic Syndrome","Recurrent Acute Myeloid Leukemia","Recurrent Myelodysplastic Syndrome","Refractory Acute Myeloid Leukemia","Refractory Myelodysplastic Syndrome"],"enrollment":52,"completionDate":"2027-12-31"},{"nctId":"NCT04047641","phase":"PHASE1,PHASE2","title":"Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-10-22","conditions":["Acute Myeloid Leukemia","Blasts 20 Percent or More of Bone Marrow Nucleated Cells","High Risk Myelodysplastic Syndrome","Recurrent Acute Biphenotypic Leukemia","Recurrent Acute Myeloid Leukemia","Recurrent High Risk Myelodysplastic Syndrome","Refractory Acute Myeloid Leukemia","Refractory High Risk Myelodysplastic Syndrome"],"enrollment":80,"completionDate":"2027-12-31"},{"nctId":"NCT06824168","phase":"PHASE2","title":"Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2025-07-18","conditions":["Acute Myeloid Leukemia","Leukemia"],"enrollment":130,"completionDate":"2032-07-14"},{"nctId":"NCT06740799","phase":"PHASE1","title":"Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic Impairment","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2024-09-30","conditions":["Hepatic Impairment"],"enrollment":12,"completionDate":"2026-03-01"},{"nctId":"NCT04493138","phase":"PHASE1,PHASE2","title":"Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-07-21","conditions":["Chronic Myelomonocytic Leukemia","Myelodysplastic Syndrome","Myeloproliferative Neoplasm","Recurrent Chronic Myelomonocytic Leukemia","Recurrent Myelodysplastic Syndrome","Recurrent Myeloproliferative Neoplasm"],"enrollment":58,"completionDate":"2027-12-31"},{"nctId":"NCT04777916","phase":"","title":"Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML)","status":"RECRUITING","sponsor":"Acute Leukemia French Association","startDate":"2022-04-14","conditions":["Acute Myeloid Leukemia (AML)"],"enrollment":5000,"completionDate":"2046-04-01"},{"nctId":"NCT03793478","phase":"PHASE1,PHASE2","title":"Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2018-08-15","conditions":["Acute Myeloid Leukemia"],"enrollment":65,"completionDate":"2027-05-01"},{"nctId":"NCT06262438","phase":"PHASE2","title":"CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients","status":"RECRUITING","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2024-02-06","conditions":["Acute Myeloid Leukemia in Children"],"enrollment":60,"completionDate":"2032-06"},{"nctId":"NCT06772246","phase":"PHASE1","title":"A Study to Evaluate QTc Prolongation With Quizartinib in Healthy Subjects Under Rapid Acceleration of Heart Rate","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2024-10-24","conditions":["Healthy Subjects"],"enrollment":70,"completionDate":"2025-06-12"},{"nctId":"NCT01892371","phase":"PHASE1,PHASE2","title":"Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-11-12","conditions":["FLT3 Gene Mutation Negative","FLT3 Internal Tandem Duplication Positive","Recurrent Acute Myeloid Leukemia","Recurrent Chronic Myelomonocytic Leukemia","Recurrent Myelodysplastic Syndrome","Refractory Acute Myeloid Leukemia","Refractory Chronic Myelomonocytic Leukemia","Refractory Myelodysplastic Syndrome"],"enrollment":73,"completionDate":"2023-02-07"},{"nctId":"NCT04477291","phase":"PHASE1","title":"A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS","status":"TERMINATED","sponsor":"Aptose Biosciences Inc.","startDate":"2020-10-06","conditions":["Acute Myeloid Leukemia","Myelodysplastic Syndromes"],"enrollment":45,"completionDate":"2024-04-15"},{"nctId":"NCT02834390","phase":"PHASE1","title":"Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2016-08-12","conditions":["Acute Myeloid Leukemia"],"enrollment":7,"completionDate":"2017-10-19"},{"nctId":"NCT06740825","phase":"PHASE1","title":"Study to Assess the Effect of a CYP3A Weak Inducer Rufinamide on Quizartinib Pharmacokinetics in Healthy Subjects","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2024-10-29","conditions":["Healthy Subjects"],"enrollment":32,"completionDate":"2024-12-09"},{"nctId":"NCT03735875","phase":"PHASE1,PHASE2","title":"Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-01-25","conditions":["Acute Myeloid Leukemia With FLT3/ITD Mutation","Recurrent Acute Myeloid Leukemia","Refractory Acute Leukemia"],"enrollment":8,"completionDate":"2023-07-26"},{"nctId":"NCT02668653","phase":"PHASE3","title":"Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"Daiichi Sankyo","isPivotal":true,"startDate":"2016-09-01","conditions":["Acute Myeloid Leukemia","Leukemia"],"enrollment":539,"completionDate":"2023-06-16"},{"nctId":"NCT04209725","phase":"PHASE2","title":"A Study of CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"SCRI Development Innovations, LLC","startDate":"2020-06-03","conditions":["Leukemia, Myeloid, Acute"],"enrollment":1,"completionDate":"2021-04-20"},{"nctId":"NCT04473664","phase":"PHASE1","title":"A Study of Quizartinib Pharmacokinetics in Participants With Moderate Hepatic Impairment","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2020-09-22","conditions":["Hepatic Impairment","Moderate Impaired Hepatic Function"],"enrollment":12,"completionDate":"2021-07-22"},{"nctId":"NCT04796831","phase":"PHASE1","title":"A Study to Determine the Absolute Oral Bioavailability of Quizartinib Using a Radiolabeled Microtracer in Healthy Subjects","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2021-04-26","conditions":["Healthy Subjects"],"enrollment":8,"completionDate":"2021-06-11"},{"nctId":"NCT03989713","phase":"PHASE2","title":"Quizartinib and High-dose Ara-C Plus Mitoxantrone in Relapsed/Refractory AML With FLT3-ITD","status":"TERMINATED","sponsor":"Prof. Dr. Richard F Schlenk","startDate":"2020-07-17","conditions":["AML According to WHO 2016 Classification (Except Acute Promyelocytic Leukemia) AND (Refractory to Induction Therapy OR Relapsed After First Line Treatment)"],"enrollment":11,"completionDate":"2022-09-11"},{"nctId":"NCT04687761","phase":"PHASE1,PHASE2","title":"Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old","status":"UNKNOWN","sponsor":"PETHEMA Foundation","startDate":"2020-11-04","conditions":["Leukemia, Myeloid, Acute","De Novo","Age More 60yr"],"enrollment":84,"completionDate":"2024-11"},{"nctId":"NCT03723681","phase":"PHASE1","title":"Study of Quizartinib in Combination With Standard Therapies in Chinese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2018-11-05","conditions":["Acute Myeloid Leukemia (AML)"],"enrollment":7,"completionDate":"2022-03-03"},{"nctId":"NCT04459598","phase":"PHASE1","title":"A Study of the Effect of a Moderate CYP3A Inducer Efavirenz on Quizartinib Pharmacokinetics in Healthy Participants","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2020-08-19","conditions":["Healthy Subjects","Drug-drug Interaction","Pharmacokinetics","Quizartinib"],"enrollment":32,"completionDate":"2020-10-14"},{"nctId":"NCT04676243","phase":"PHASE3","title":"Daunorubicin or Idarubicin With Cytarabine Plus Quizartinib vs Physician's Choice in Newly Diagnosed FLT3-ITD+ AML","status":"WITHDRAWN","sponsor":"University Hospital Heidelberg","startDate":"2022-05","conditions":["Acute Myeloid Leukemia"],"enrollment":0,"completionDate":"2025-12"},{"nctId":"NCT03552029","phase":"PHASE1","title":"Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)","status":"TERMINATED","sponsor":"Daiichi Sankyo","startDate":"2018-12-12","conditions":["Acute Myeloid Leukemia"],"enrollment":10,"completionDate":"2021-04-01"},{"nctId":"NCT01411267","phase":"PHASE1","title":"AC220 for Children With Relapsed/Refractory ALL or AML","status":"COMPLETED","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2011-09-01","conditions":["Lymphoblastic Leukemia, Acute, Childhood","Myelogenous Leukemia, Acute, Childhood"],"enrollment":24,"completionDate":"2013-09-12"},{"nctId":"NCT04112589","phase":"PHASE1,PHASE2","title":"A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First Treatment","status":"UNKNOWN","sponsor":"PETHEMA Foundation","startDate":"2019-12-26","conditions":["Acute Myeloid Leukemia"],"enrollment":63,"completionDate":"2023-12"},{"nctId":"NCT04459585","phase":"EARLY_PHASE1","title":"A Study of the Effect of Quizartinib on the Pharmacokinetics of the P-gp Substrate Dabigatran Etexilate in Healthy Participants","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2020-08-28","conditions":["Healthy Subjects","Drug-drug Interaction","Pharmacokinetics","Quizartinib"],"enrollment":20,"completionDate":"2020-10-20"},{"nctId":"NCT02039726","phase":"PHASE3","title":"(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2014-05","conditions":["AML"],"enrollment":367,"completionDate":"2020-09-08"},{"nctId":"NCT03135054","phase":"PHASE2","title":"Combination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITD","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2017-10-01","conditions":["AML","FLT3-ITD Mutation"],"enrollment":40,"completionDate":"2021-10-01"},{"nctId":"NCT00462761","phase":"PHASE1","title":"A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2007-01","conditions":["Acute Myeloid Leukemia","Leukemia","Myelodysplastic Syndrome","AML","MDS"],"enrollment":76,"completionDate":"2009-12"},{"nctId":"NCT03746912","phase":"","title":"Expanded Treatment Protocol for Adults With FLT3-ITD Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) to Receive Quizartinib","status":"NO_LONGER_AVAILABLE","sponsor":"Daiichi Sankyo","startDate":"","conditions":["Acute Myeloid Leukemia With Gene Mutations"],"enrollment":0,"completionDate":""},{"nctId":"NCT02984995","phase":"PHASE2","title":"Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2016-12-08","conditions":["Leukemia, Myeloid, Acute"],"enrollment":37,"completionDate":"2018-09-14"},{"nctId":"NCT01565668","phase":"PHASE2","title":"Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2012-04","conditions":["Leukemia, Myeloid, Acute"],"enrollment":76,"completionDate":"2015-03"},{"nctId":"NCT00989261","phase":"PHASE2","title":"Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2009-11","conditions":["Acute Myeloid Leukemia"],"enrollment":333,"completionDate":"2014-12-31"},{"nctId":"NCT01390337","phase":"PHASE1","title":"A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2011-10","conditions":["Leukemia, Myeloid, Acute"],"enrollment":19,"completionDate":"2015-02"},{"nctId":"NCT02675478","phase":"PHASE1","title":"Phase 1 Study of Quizartinib","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2016-02","conditions":["Relapsed AML","Refractory AML"],"enrollment":17,"completionDate":"2018-11-13"},{"nctId":"NCT01049893","phase":"PHASE1","title":"Dose Finding, Safety and Tolerability Study for AC220 to Treat Advanced Solid Tumors","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2010-01","conditions":["Solid Tumors"],"enrollment":45,"completionDate":"2011-11"},{"nctId":"NCT01468467","phase":"PHASE1","title":"A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2012-04","conditions":["Leukemia, Myeloid, Acute"],"enrollment":13,"completionDate":"2015-03"},{"nctId":"NCT02829840","phase":"PHASE1,PHASE2","title":"Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-09","conditions":["Leukemia","FLT3-Mutated Acute Myeloid Leukemia","FLT3-Mutated High-Risk Myelodysplastic Syndrome"],"enrollment":0,"completionDate":""},{"nctId":"NCT01576185","phase":"","title":"Developing and Treating a Mouse Model of Acute Myeloid Leukemia Using Tissue Samples From Younger Patients With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2012-05","conditions":["Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies"],"enrollment":10,"completionDate":"2016-05"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"pivotalTrials":["NCT02668653"],"administration":{"route":"Oral","formulation":"Tablet","formulations":[{"form":"TABLET, FILM COATED","route":"ORAL","productName":"VANFLYTA"}]},"_patentsChecked":true,"crossReferences":{"MMSL":"41829","NDDF":"019499","UNII":"7LA4O6Q0D3","CHEBI":"CHEBI:90217","INN_ID":"9356","RXNORM":"2643048","UMLSCUI":"C2980091","chemblId":"CHEMBL576982","ChEMBL_ID":"CHEMBL576982","KEGG_DRUG":"D09956","DRUGBANK_ID":"DB12874","PDB_CHEM_ID":" P30","PUBCHEM_CID":"24889392","IUPHAR_LIGAND_ID":"5658","SECONDARY_CAS_RN":"1132827-21-4","MESH_SUPPLEMENTAL_RECORD_UI":"C544967"},"formularyStatus":[],"originalProduct":{"form":"TABLET, FILM COATED","route":"ORAL","company":"Daiichi Sankyo Inc.","brandName":"VANFLYTA","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2023-","companyName":"Daiichi Sankyo Inc ","relationship":"Original Developer"},{"period":"present","companyName":"Daiichi Sankyo Inc","relationship":"Current Owner"},{"period":"2019","companyName":"Daiichi Sankyo Company, Limited","relationship":"PMDA Licensee"}],"publicationCount":371,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"L01EX11","allCodes":["L01EX11"]},"biosimilarFilings":[],"originalDeveloper":"Daiichi Sankyo Inc ","recentPublications":[],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"Daiichi Sankyo Inc","companyId":"daiichi-sankyo","modality":"Small molecule","firstApprovalDate":"2023","enrichmentLevel":4,"visitCount":0,"regulatoryByCountry":[{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"2019-06-18T00:00:00.000Z","mah":"DAIICHI SANKYO COMPANY, LIMITED","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-07-20T00:00:00.000Z","mah":"DAIICHI SANKYO INC ","brand_name_local":null,"application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"2023-07-20T00:00:00.000Z","mah":"DAIICHI SANKYO INC ","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"2023-07-20T00:00:00.000Z","mah":"DAIICHI SANKYO INC ","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"2023-07-20T00:00:00.000Z","mah":"DAIICHI SANKYO INC ","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"2023-07-20T00:00:00.000Z","mah":"DAIICHI SANKYO INC ","brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-07-20T00:00:00.000Z","mah":"DAIICHI SANKYO INC","brand_name_local":null,"application_number":"NDA216993"},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"2023-07-20T00:00:00.000Z","mah":"DAIICHI SANKYO INC ","brand_name_local":null,"application_number":null},{"country_code":"BE","regulator":"FAMHP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vanflyta","application_number":null},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vanflyta","application_number":"EMEA/H/C/005910"},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vanflyta","application_number":null},{"country_code":"BG","regulator":"BDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vanflyta","application_number":null},{"country_code":"HR","regulator":"HALMED","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vanflyta","application_number":null},{"country_code":"CY","regulator":"PHS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vanflyta","application_number":null},{"country_code":"CZ","regulator":"SUKL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vanflyta","application_number":null},{"country_code":"DK","regulator":"DKMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vanflyta","application_number":null},{"country_code":"EE","regulator":"SAM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vanflyta","application_number":null},{"country_code":"FI","regulator":"Fimea","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vanflyta","application_number":null},{"country_code":"FR","regulator":"ANSM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vanflyta","application_number":null},{"country_code":"DE","regulator":"BfArM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vanflyta","application_number":null},{"country_code":"GR","regulator":"EOF","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vanflyta","application_number":null},{"country_code":"HU","regulator":"OGYEI","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vanflyta","application_number":null},{"country_code":"IE","regulator":"HPRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vanflyta","application_number":null},{"country_code":"IT","regulator":"AIFA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vanflyta","application_number":null},{"country_code":"LV","regulator":"ZVA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vanflyta","application_number":null},{"country_code":"LT","regulator":"VVKT","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vanflyta","application_number":null},{"country_code":"LU","regulator":"MS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vanflyta","application_number":null},{"country_code":"MT","regulator":"MMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vanflyta","application_number":null},{"country_code":"NL","regulator":"MEB","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vanflyta","application_number":null},{"country_code":"PL","regulator":"URPL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vanflyta","application_number":null},{"country_code":"PT","regulator":"Infarmed","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vanflyta","application_number":null},{"country_code":"RO","regulator":"ANMDMR","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vanflyta","application_number":null},{"country_code":"SK","regulator":"SIDC","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vanflyta","application_number":null},{"country_code":"SI","regulator":"JAZMP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vanflyta","application_number":null},{"country_code":"ES","regulator":"AEMPS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vanflyta","application_number":null},{"country_code":"SE","regulator":"MPA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vanflyta","application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"AU","regulator":"TGA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vanflyta","application_number":null},{"country_code":"CH","regulator":"Swissmedic","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vanflyta","application_number":null},{"country_code":"NO","regulator":"NoMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vanflyta","application_number":null},{"country_code":"IS","regulator":"IMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vanflyta","application_number":null},{"country_code":"NZ","regulator":"Medsafe","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vanflyta","application_number":null},{"country_code":"AT","regulator":"AGES","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vanflyta","application_number":null}],"trialStats":{"total":11,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:48:29.446859+00:00","fieldsConflicting":5,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}